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Abstract 
The effect of diabetes mellitus on the endodontic lesion is poorly understood and has 
undergone little study. The objective of this study was to determine the effect of diabetes on 
in utro steoclast development, following bacterial stimulation, and bone formation. Thirty-
nine diabetic and thirty-eight genetically-matched control mice were divided into eight 
groups and injected with P. gj,ngi,mlis. The mice were sacrificed on designated days. The 
marrow stromal cells were then harvested from each group. The cells were cultured for 
osteoclastic cell development and bone formation. Following a 21-day incubation period, 
the cultures were stained with TRAP (osteoclastic cells) or von Kossa's technique (bone 
nodules). The osteoclasts were microscopically enumerated and the amount of bone nodule 
formation was quantified using ImagePro software. Statistical significance of the means was 
determined using Scheff e's post-hoc comparison. Following in utro LPS stimulation, 
osteoclast formation was found to be higher in the diabetic groups at day O and remained 
high at day 5, at which time the normal control groups reached a comparable level. 
Paradoxically, the diabetic culture also had significantly higher bone nodule formation than 
the control group. The present study indicates that accelerated and prolonged bone 
resorption may occur in diabetic animals followed by an increase in bone formation. Based 
on previous findings by others, the expedited bone remodeling leads to a lower density of 
the bone in diabetics. These findings may partially explain why endodontic lesions in 
diabetics are more prevalent, larger in size, and demonstrate delayed healing. 
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Part I: Diabetes Mellitus 
I. Introduction 
Science has advanced at a phenomenal rate over the past twenty years. Not only has the 
depth increased but the breadth has increased opening the door to a plethora of questions. 
As a society we have placed an ever-increasing value on finding answers to questions related 
to the human body and the diseases which present themselves. Demographics have 
influenced our focus to reflect our aging society and the diseases we may be afflicted with as 
we age. One such disease, diabetes mellitus, is currently at epidemic levels in the United 
States, according to the American Diabetes Association. They also report that it is the sixth 
leading cause of death by disease. Overall in the US, diabetes mellitus affects over seventeen 
million people, one third of them undiagnosed. Its predominance is increasing with a 
population bulge that is aging, overweight, and increasingly sedentary. Ensuing long term 
sequelae of this disease include: cardiovascular disease and stroke, high blood pressure, lower 
limb amputations, diabetic eye disease, kidney disease, nervous system disorders, and a 
higher susceptibility to infectious illnesses. Other sequelae of the disease include bone 
defect related dental complications such as delayed wound healing in endodontic lesions and 
severe periodontal disease. As a result, the American Diabetes Association estimates that 
Americans spend an estimated $132 billion per year on direct and indirect costs associated 
with diabetes. Diabetes is therefore a high cost to society. The disease primarily presents in 
two forms: type 1, also known as insulin-dependent diabetes (IDD1v1), and type II diabetes, 
also termed non-insulin dependent diabetes (NIDD1v1). Although their etiologies differ, they 
share the common symptoms of hyperglycemia and hyperlipidemia. Approximately ninety 
percent of presenting diabetic cases are type II. Although this disease exacts a huge toll on 
society, little is known regarding how type II diabetes alters the host response to bacteria in 
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general, and oral pathogens in particular. A breakthrough in understanding the mechanisms 
leading to type II occurred with the discovery that obese mice have defects in insulin 
receptor signaling. 
The availability of a suitable diabetic animal model affords the research community the 
ability to examine the disorder under detail, thereby providing insight into the corresponding 
human disease. In essence, this research involves studying osteoclast formation in mouse 
marrow cell cultures of diabetic mice. In this study, factors including vitamin D and 
macrophage colony stimulating factors are included in the cell growth media to direct 
marrow cell growth into the osteoclast lineage. The osteoclasts are then stimulated with 
varying concentrations of lipopolysaccharide (LPS), a potent bacterial product, to determine 
the concentration most encouraging to osteoclast formation. The increased formation of 
osteoclasts directly relates to the diabetics' susceptibility to bone loss. This then relates to 
diabetic individuals being more susceptible to tooth loss; accelerated in people who are 
genetically vulnerable to periodontal disease or have endodontic lesions. We are anticipating 
that the information we winnow will also allow development in adjacent research areas 
including osteopathic diseases. This would then play major roles in people's lives from 
extending the life of people's natural dentition to limiting bone loss and ensuing loss of 
function. 
The second aspect of this research entails establishing a mineralizing matrix or bone nodule 
formation again using the diabetic mouse marrow. A variety of factors, including ~-
glycerophosphate, dexamethasone, and ascorbic acid are added to the cell culture which 
direct cell growth to the osteoblastic direction. Following the nutrient bathed incubation 
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period, the cells are stained and the area of bone formation is analyzed by computer assisted 
image analysis. Although the problem still involves diabetics and bone loss, this approach is 
opposite in compa1~son to the preceding experiment by utilization of bone forming cells 
rather than bone resorbing cells. In the future this will hopefully allow the introduction of 
chemicals or natural substances into the mouth or other areas of bone loss and allow the 
inductwn of bone formation. This study will provide direct information on whether diabetes 
affects osteoclast and/ or osteoblast formation by bone marrow, and give some insight into 
the mechanisms by which diabetes results in abnormal bone remodeling, excessive bone 
resorption or delayed formation or both. Therefore, in uniting the results of these 
expe1ruents, this will hopefully give greater insight in retarding bone loss and inciting its' 
formation. This is a thrilling area of research which will have a positive effect on millions of 
people around the world for years to come. 
3 
The Impact of Diabetes Mellitus on Bone 
Studies using diabetic mice and rats correlate well with experiments on diabetic humans. 
Patients with diabetes display higher levels of some markers of bone resorption including 
urinary calcium, hydroxyproline, and telopeptides than in control subjects .' Bone turnover 
in adult humans is summarized by Krakauer et . al. who report that diabetics present with a 
low bon e formation rate.2 Type I diabetics display bone loss early in life due to the 
metabolic effects of poor glycemic control, not necessarily followed later in life by 
progressi ve bone loss. The type II diabetic tends to show low bone turnover, which retards 
bone loss. This results in type II diabetics actually showing bone density that exceeds the 
expectation for their age, but increased stress fractures due to the reduced bone remodeling. 
Given the fact that the diabetic mice and rats have uncontrolled glucose levels they would 
tend to follow the findings of progressive bone loss early in the life a type I diabetic who is 
uncontrolled with respect to glucose levels. 
Diabetic mice can be produced in a number of ways. Introducing a point mutation in the 
leptin receptor gene, Lepr, yields the diabetic strain BKS.Cg-m +/ + Leprdb. -3'4'5'67 The leptin 
ligand has been shown to be a key weight control hormone that is mutated in the mouse 
obesity mutation, Lepob. This point mutation promotes abnormal splicing, creating a stop 
codon that shortens the intracellular domain of the receptor, eliminating its signaling 
capacity. This strain is maintained with m and Leprdb in repulsion. Although there is a 
remote possibility of recombination, they are tightly linked. The mice are thus distributed 
with the assumption that they are not recombined, this is untested at delivery, however. To 
ensure that they are diabetic, their glucose levels are clinically checked over a period of two 
weeks prior to the experiment start date. These mice begin to phenotypically display the 
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genetic mutation at approximately 3-4 weeks of age. Plasma insulin is increased at 10-14 
days and blood sugar increases at 4-8 weeks. As in the diabetic human, they are also 
polyphagic, polydipsic, and polyuric. On the C57BLKS background, utilized in our 
experiment, there is a noticeable rise in blood sugar, severe depletion of the insulin-
producing beta-cells of the pancreatic islets, and a shorted lifespan typically ending at 10 
months of age. As a result of these characteristics, these mice serve as a useful experimental 
diabetic model to further explore bone turnover in diabetics. 
The effect of high glucose on osteob last-like cells has been examined in a variety of ways. 
Some findings indicate that the high levels of glucose significantly impair the proliferative 
response of osteoblastic cells to IGF-I and that the defective cell function caused by 
sustained glucose levels may contribute to impaired bone formation. 8 The effect of high 
glucose levels on nodule formation in vitro has also been examined. 9 These researchers 
noted that osteoblast (OB) cellular proliferation and alkaline phosphatase activity was 
significantly increased in the presence of glucose, whereas calcium uptake was inhibited. 
Research has noted that calcium homeostasis is impaired in the diabetic condition however 
at this point it is unknown whether cell calcium regulation precedes or succeeds the overt 
diabetic condition. to Therefore, glucose inhibition of calcium uptake could cause bone to be 
structurall y altered in diabetics. Studies on the influence of high glucose on 1,25-
dihydroxyvitamin D 3-induced effect on human osteoblast-like MG-63 cells show that high 
glucose concentration limits the ability of osteoblastic cells to synthesize osteocalcin in 
response to 1,25(0H) 2D 3 by reducing the vitamin D receptor number. L1 These same 
researchers also demonstrated that poor glycemic control impairs the responses of 
osteoblasts and osteoclasts to 1,25(0H):P 3 in normo-insulinemic type II diabetic patients. 12 
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Thus there are numerous causes of impaired cellular function by elevated glucose levels that 
contribute to the bone formation defect in diabetics which include: the impaired 
proliferation of OBs to I GF- I in vivo, the elevated proliferation of OBs and decreased 
calcium uptake in vitro, and the limited ability of OBs to synthesize osteocalcin in response 
to vitamin D. 
Previous research on diabetic mice has yielded important information with respect to bone 
formation. Shyng et. al. used Streptozotocin induced diabetic rats and found they exhibited 
reduced cancellous bone volume and bone formation in the femur revealing a flaw in 
mineralization or osteoid formation when compared with controls. D The measure of length, 
dry weight, ash weight, and calcium content in the tibia also illustrated a noticeable decrease 
when compared with the controls. A similar experiment carried out by Hosokawa 
investigated bone metabolism in db/ db mice.14 This study found that the wet, dry, and 
ashed weights and lengths of the femur in the db/ db was also less than in the controls. 
They additionally found cortical bone thinning which they postulate may have been a result 
of increased bone resorption. Their results seem to indicate that retarded bone growth in 
db/ db is related to the progression of diabetes. Suzuki et. al. tested circulating levels of 
tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus 
(NIDDM) in Wistar fatty rats and neonatally streptozotocin-induced diabetic rats. 15 
Comparable to other experiments they found reduced bone length, strength, and weight and 
elevated plasma 1RACP, also known as TRAP or TR-AP, when compared with the controls 
in the Wistar fatty rats. Interestingl y, they found that the NSZ rats had significantly lower 
plasma TRACP levels than their controls. They also found positive correlations between 
circulating 1RACP and insulin levels in both NIDDM rat models. Decreased osteocalcin 
6 
levels were noted in both NIDDM models. In their conclusions, they suggest that bone 
formation by osteoblasts was reduced while the osteoclastic bone resorption was increased 
in the Wistar fatty rats with hyperinsulinemia. However, in the NSZ rats with 
hypoinsulinemia, both the bone formation and resorption were decreased, correlating with 
the decreased bone turnover. They thus suggest that the osteoblastic model is homogeneous 
in NIDDM models, whereas the osteoclastic function is heterogeneous under NIDDM 
conditions . Another experiment by Maruo et. al. examined histopathological changes in the 
tissue under denture bases in diabetic rats.16 Effects relevant to our study include: (1) 
enhanced inflammatory change and its extended appearance in time (2) reduced threshold 
for the inflammatory reaction induced by the masticatory pressure, (3) increased number of 
osteoclasts and prolonged period of presence, (4) reduced threshold for osteoclastic bone 
resorption induced by the masticatory pressure, and (5) inhibition of the appearance of 
osteoblasts following the disappearance of osteoclasts. Overall, these studies assist in 
furnishing a solid framework of cellular function in the osteoclasts and osteoblasts in 
diabetic mice. 
Bone Matrow 
The bone marrow acts as a reservoir of hematopoietic and non-hematopoietic stem cells, 
also termed marrow stromal cells (MSCs) or mesenchymal stem cells. The hematopoietic 
stem cells must serve as a continuous source of progenitors for red blood cells, platelets, 
monocytes, granulocytes and lymphocytes. 17 These stromal cells exhibit a multipotential 
nature and function as precursors of osteoblasts, fibroblasts, myoblasts, chondroblasts, and 
adipoblasts .18 In the embryo and newborn, all bone cavities are occupied by red 
hematopoietic marrow. In an adult, the red marrow is only found in the ribs, sternum, 
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vertebrae, skull, and humerous; the remaining majority of marrow changes to the yellow, 
fatty, inactive marrow. Besides being primarily located in bone marrow, MSG are also 
found in periosteum, muscle connective tissue, 19'20 fetal bone marrow, liver and blood. 21 
Mouse Marrow Cultures 
In the study of MSC lines, the mouse is an attractive animal model given it's close relations 
to the gene set of the human model, affordable associated costs, and their high percentage of 
hematopoietic cells compared with human marrow which have less than 30%.22·23 Since the 
MSG serve as the precursor of osteoblasts and hence osteoclasts, they are a useful 
springboard for studying both bone formation and resorption. 
In the laboratory setting, Fibbe describes some of the difficulties when utilizing MSC 
cultures. 24 Currently, there is no defining phenotype that allows MSC precursors to be 
isolated reproducibly with a predictable developmental potential. As a result, isolating and 
developing stromal cell function is based on their adherence to plastic and their expansion 
potential. In fact, this method follows original isolation techniques of MSG, as described by 
Friedenstein, who also isolated this cell lineage by means of their adherence to plastic.25 
Another solution to this problem is also available through their differentiation potential as a 
defining potential. 8 MSG differentiate into osteoblasts, chondrocytes and adipocytes in 
response to dexamethasone, 1,25-dihyroxyvitamin D 1, or cytokines such as BMP-
9 2" "3 ?6 27 28 ,,9 H d"ff . . f h 1 d 11 . . if. d b d 2. ' -,- ,- ' ' ·- owever, 1 erent1at1on o t e cu ture ce s 1s species-spec ic an ase on a 
variety of poorly understood va1~ables, such as the lot of fetal bovine semm (FBS) 
employed. 30 The inclusion of FBS in the media, however, provides the necessary conditions 
to allow the cells to spread. Finally, their growth is also influenced by cell density; below a 
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certain level of cell numbers, cult11res often fail. This may be a result of reduced cellular 
interaction, especially when combined with the fact that there is a certain level of cell deaths 
in cell cultures. Thus, the culture of MSCs requires adherence to important parameters to 
provide favorable results. 
Further exploration in the area of MSCs is required, as outlined by Fibbe. 8 A greater 
understanding of progenitor cells and their function in osteogenic and chondrogenic 
differentiation and development would be useful. Are MSCs that are derived from diabetic 
animals functionally similar to non-diabetic ones? Do MSCs from culture keep their self-
renewal and multilineage differentiation potential in diabetic animals? The answers to these 
questions will point us in new directions and advance useful clinical therapies. 
Bone Remodeling 
Every year ten percent of the skeletal mass in humans undergoes remodeling, serving a 
variety of functions. These include maintaining support of the body, allowing movement, 
incubating the developing immune cells, maintaining systemic mineral homeostasis, and 
maintaining stability of the tissue by the repair of mechanically induced microfractures. 31 In 
trabecular bone the rate of remodeling, twenty-five percent, is comparatively higher than the 
three percent of cortical bone which is remodeled, illustrating that local factors are 
responsible for initiating the process. 32'33 Alveolar ridge bone remodeling occurs at the 
quickest rate in the body's attempt to repair the microdamage that results from the strong 
masticatory forces. The remodeling process is uniquely coupled throughout life alternating 
between bone resotption by osteoclasts and bone formation by osteoblasts; these groups of 
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cells are known as basic multicellular units (BMUs) .34 Should this balance be upset, a 
number of pathological conditions can occur including diseases such as diabetes. 
Bone Fonnation: Osteoblasts and Bone Matrix Proteins 
Bone formation involves a series of cells working in concert. These include: stromal 
osteoprogenitor cells which serve to maintain the osteoblast population and bone mass, 
osteoblasts functioning to produce bone matrix in an organized manner, osteocytes acting to 
support bone structure, and bone lining cells which protect the bone. The largest 
component of bone is type 1 collagen. Included in bone are a number of non-collagenous 
proteins including: osteocalcin, osteonectin, osteopontin, bone sialoprotein, matrix Gla 
protein, thrombospondin, biglycan and others. 
OBs are derived from red and yellow marrow, through the pluripotent mesenchymal lineage 
of cells. Their formation consists of a multistep process regulated by an integrated cascade 
of gene expression that initially supports proliferation and the sequential expression of genes 
that contribute to bios)mthesis and formation of bone tissue.35 
The mature OBs lay down new bone mat1ix in the form of osteoid, which later becomes 
calcified to form mature bone. Thus they are basophilic due to the abundance of rough 
endoplasmic reticulum for the production of collagen and proteoglycans. During bone 
formation the OBs may become embedded in the bone matrix and differentiate into 
osteocytes. Throughout their life, OBs control the activation and resorption of preformed 
osteoclasts. This is demonstrated by the requirement of mixtures of OBs and osteoclasts in 
order for bone resorption to occur. In diabetics it has been demonstrated that decreased 
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osteoblast activity is present at the onset of diabetes and is dependent on endogenous 
corticosterone and is not reproduced by hyperglycemia in nondiabetic rats.36 Another study 
on diabetes noted that diabetic osteopenia may be a result of reduced numbers of osteoblasts 
and deminished osteoid. 37 Bone remodeling is partially controlled by cytokines acting on 
OBs receptors; PTH, vitamin D 3, and estrogen are among these cytokines. 
Mineralizing Matrix (Nodule Fonnation) 
There has been a lot of research in the area of in vitro bone- like mineralized tissue formation 
from bone marrow-derived mesenchymal cells. The osteogenic media typically includes 
ascorbic acid (vitamin C), ~-glycerophosphate, and the synthetic glucocorticoid 
dexamethasone (Dex). 38•39'40·41•42•4-' Dexamethasone has been noted be necessary for induction 
of nodule formation in a variety of culture systems.26'27 Its inclusion in the culture has also 
resulted in increased nodule formation. 44 Culturing purified MSG with dexamethasone and 
ascorbic acid causes temporary induction of alkaline phosphatase, exhibiting bone matrix 
protein mRNAses, and calcium deposition. 45 Ascorbate is an enzyme cofactor and 
antioxidant acting to stimulate transcription, translation, and posttranslational processing of 
collagen in connective tissue cells.46 The inclusion of ascorbate in bone derived cell cultures 
stimulates osteoblastic differentiation, synthesis, and deposition of collagen as well as 
mineralization. 47'48 '49 Experiments investigating how glucose affects bone formation found 
that at the time of matrix maturation there is a noticeable decrease of calcium uptake in 
cultures with the presence of glucose.50 They also noted that the addition of glucose to 
culture has the effect of increasing both the number of nodules and the total nodular area. 
Another su1dy has noted that in using CFU-F progen y, a percentage of the cells seem to 
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exhibit osteogenic potential and become positive for alkaline phosphatase; they are able to 
form foci of mineralized bone and therefore must have osteoprogenitor cells.51 This 
supports the link between marrow-derived osteoprogenitor cells and bone remodeling and 
repair in human adults as well as provides insight into the effects of the diabetic model on 
bone formation. 
In vitro, osteoblasts synthesize an EOv1 that undergoes mineralization with the introduction 
of a mineral source. 52 Although mineralization occurs, the primary problem, as addressed by 
Lian et al., is that few studies show that the mineral formed actually was bone-like apatite.31 
Stains such as von Kossa, which stain for phosphate, tend to shed the least information on 
this issue. Since a positive reaction occurs when anions react with both complex silver and 
all phosphate-containing materials, a distinction does not occur between apatite and 
membranes. However, the density of the stain is helpful and allows nodule formation to 
form dark clusters easily measured and allowing easy comparison between diabetic and non-
diabetic models. Ideally the staining issue is resolved with the use of electron micrographs 
complete with electron-diffraction analyses, which provide strncture verification. As well, 
other diffraction methods, including nuclear magnetic resonance and infrared methods can 
be applied to yield absolute results. Although these options are more readily available today 
than in the past, their application in the typical laboratory setting is still often cost 
prohibitive. As a result, von Kossa staining is still typically employed in bon e nodule 
expenments. 
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Bone Mo1phogenic Protein 
The factor which likely initiates movement to the osteoblastic lineage is bone morphogenetic 
proteins (BMPs), which is a member of the transforming growth factor ~ TGF- ~ 
superfamily. 2 Marshall R. Urist first realized that a substance could induce new bone 
formation in 1965.53 Twenty years later, Wozne y et al. identified the genetic sequence of 
bone morphogenetic protein (BMP);54 today, thirteen BMPs have been identified. 55 BMPs 
bind through complicated mechanisms to specific receptors on numerous cell types 
including mesenchymal stem cells, osteoblasts, and osteoclasts. The signal is then 
transduced through a group of proteins called Smads; secondary messages are then conveyed 
into the cytoplasm. The BMPs cause differentiation from marrow stromal cells in response 
to activation of the transcription factor they produce, core binding factor al (Cbfal), also 
known as osteoblast specific factor 2 (Osf2).56 This factor activates osteoblast specific genes 
inducing production of alkaline phosphatase, one of the earliest phenotypic markers of the 
committed post-proliferati ve osteoblast . Other phenotypic markers include: osteopontin, 
bone sialoprotein, type I procollagen, and ostocalcin, a late-stage marker found in mature 
OBs producing a mineralizing matrix. 57 A further summary of their action is provided by 
Helm et al.58 
During development, BMPs have been shown to play an important role in endochondral 
and intramembranous bone formation. At low concentrations, BMPs stimulate formation of 
chondrocytes, whereas at higher concentrations direct bone formation occurs. These 
proteins have been shown to be wide acting and have expression on a wide variety of cells 
illustrated by regulating growth, differentiation, chemotaxis, and apoptosis, with roles in 
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morphogenesis of a variety of tissues and organs.59 It has been demonstrated that BJ\.11?2, 
BJ\.11?4, and their receptors are needed for organogenesis , repair and are necessary for 
osteoclast and osteoblast formation; they are also expressed in post natal bone marrow. 60 
Their importance to survival is evidenced in that mice lacking BJvlP-2, 4, and 7 die early in 
embryonic development or soon after birth.61 In the final analysis, their stimulation leads to 
direct or indirect cellular chemotaxis, proliferation, and differentiation of an 
osteochondroblastic lineage. Future study in this area is necessary to determine the BJvlP 
receptors and messenger systems in diabetic marrow cells. Given the osteogenic potential of 
these molecules, this area will definitely drive future research. 
Fibroblast Growth Factor 
Other factors influential to growth of osteoblast cell numbers are fibroblast growth factors 
(FGFs) . The FGF family are nine structurally related polypeptides which are characterized 
by their affinity for the glycosaminoglycan heparin-binding sites on cells.62•63•64 The action of 
basic FGF (bFGF) is transduc ed through signals to the cytoplasm via four receptors that 
have tyrosine kinase activity.40 bFGF is produc ed by bone cells,65•66 and is also a potent 
stimulator of PGE 2 synthesis in bone.67 FGF-1 and 2, the most abund ant FGFs in normal 
adult tissue, promot e growth and differentiation of numerous types of cells including 
epithelial cells, myocytes, osteoblasts, and chondrocytes. FGF-2, considered more potent 
than FGF-l, 68 is stored in the extracellular matrix (ECM)45·69•70• and is then released with 
osteoclastic activity,46 or at a fracture site where matrix disruption ensues.44 
FGF-2 expression occurs in osteoblasts 45,71,727 3 and osteocytes.52 Previous experiments with 
the addition of BJvlP-2 and bFGF have shown interesting results in their effect on MSC 
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cultures. 74 Adding BMP-2 to the nodule cultures did not cause a substantial increase during 
in vitro osteogenesis, however , including bFGF increased the formation of nodules 
noticeabl y. Bone cell cultures with the addition of FGF-2 have induced replication 50 and 
reduced differentiation markers such as all<aline phosphatase and type 1 collagen.75.16,77,73 
These cell markers thus allow them to be considered very early OBs. Bone formation in 
these in vitro cultures was demonstrated only with intermittent application of FGF-2. 77'79•80 
In vivo studies in rats have shown that FGF- 2 treatment has increased cancellous bone in 
the marrow cavity,60•8L thereb y demonstrating that the osteoblast precursors in the marrow 
cavity are target cells of FGF-2. 82 The osteoblast precursors/ stromal cells found in the bone 
marrow synthesize FGF-2 83 and respond to it in an autocrine/ paracrine manner. 84'85'86•87 
Factors such as transforming growth factor ~,78 prostaglandins, 52 and parathyroid hormone 73 
cause FGF-2 mRNA and protein levels to be increased in osteoblasts. Therefore, these 
factors play a role in regulation of FGF-2 production. 82 BMP and FGF are only two such 
factors that have been shown to affect bone nodule formation, however, it is universally 
accepted that the bone formation process is controlled sequentially and cooperativel y by a 
number of growth factors. 88 
Although the mechanisms for signal transduction by growth factors and their receptors have 
been delineated, little is known with respect to how these growth factors interact to regulate 
bon e repair89 or how the various pathwa ys interact with one another. Hurle y et al. have 
opened the door to more questions. 90 Although they found an increase in the MSCs that 
were stimulated with bFGF, a more definitive understanding of these pathways is cmcial for 
future clinical use of these growth factors. 
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Osteocytes 
Osteocytes are the final destination of differentiation of osteoblasts. Osteocytes, which have 
less cytoplasmic basophilia than osteoblasts, interconnect with one another and other cells 
on the bone surface via long cytoplasmic extensions. Cannaliculi in the bone matrix allow 
fluid to flow and provide space for the cytoplasmic extensions. Osteocytes are believed to 
act as sensors of mechanical stress in the skeleton by detecting and responding to changes in 
fluid. Interactions between osteocytes and osteoblasts occurs via gap-junction proteins 
called connexins .91 
Osteocytes, as well as osteoblasts and preosteoblasts, functionall y respond to endocrine 
factors. They respond by producing paracrine and autocrine factors for the recruitment of 
osteoprogenitors, growth of preosteoblasts and finally resorption by osteoclasts. 
Bone Resorption: Osteoclasts 
Osteoclasts (OG) arise from the hematopoietic stem cells, which are derived from the 
marrow cells, on a pathwa y shared with that of monocytes and macrophages. This 
knowledge has allowed experimentation of OC differentiation utilizing macrophages derived 
from various sources to develop into osteoclasts. 92 The formation of OG requires 
functional hematopoietic stem cells and signals from osteoblasts or the extracellular 
matrix.93'94 For physiological bone resorption, the osteoclastogenesis signal must occur via 
direct contact between OC precursors and stromal cells or osteoblasts. 92 As a result, OG 
can be derived in vitro utilizing a coculture of osteoblasts and spleen cells or stromal cells or 
bone marrow as a source of osteoclast precursors. 95 Recent discovery shows that 
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inflammatory bone resorption can be generated by lipopolysaccharide and inflammato ry 
cytokines includin g tumor necrosis factor receptor-a, interleukin-1, and OPGL which 
regulate OC differentiation by mechanisms independent of RANKL-RANK interaction. 96'97 
These are factors which can be provid ed by either non-stromal cells or osteoblasts. Given 
the research over the past decade, three alternate hypothesis exist as to OC development: (1) 
independent development from a specialized progenitor originating in the GM-CFU 
compartment; 98'99 (2) divergence from the M-CFU compartment; 100'1 1 or (3) late monoc ytes 
or macroph ages are direct precursors of OC. 92,102 
Their differenti ation path ways are dependent on a variety of molecules. These lineage-
specific regulatory molecules include c-fos, M-CSF, RANK, RANKL, and 
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Figure 1. Effe cts of cytokines on osteoclast production and activity. 
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osteoprotegerin. 1 3 Other stimulators include: 1,25(0H) 2 D 3 , 104 IL-1,105'106 IL-3,107 IL-6,108 IL-
11,109 TNF,1 05 P1H, 110 and PGE/ w OCdifferentiation is inhibited bycalcitonin,1 11 
intederon-y, 11~ and IL-4.m The primary method of osteoclastogenesis promotion, as 
proposed by Teitelbaum, occurs via two molecules: macrophage-colony stimulating factor 
(M-CSF) and receptor for activation of nuclear factor kappa B (NF-KB) and RANK ligand 
(RANKL) .114 Other researchers have shown that bFGF increases the formation of CFU-
GM (colony-forming unit for granulocytes and macrophages), the immediate progenitor to 
the OC in human marrow cultures, leading to speculation that this may be an additional 
pathway. 115 Some of these cytokines and their effect on osteoclast development and 
production can be seen in Figure 1.116 
Osteoclasts are differentiated from other cells by a group of phenotypic markers. These 
include the presence of: multinucleation, ruffled border, podosomal ring, tartrate- resistant 
acid phosphatase (TRAP), cathepsin K, proton pump subunit OC116 (ATP6I), carbonic 
anhydrase II, vitronectin receptor (av~3 integrin), calcitonin receptor, and functional bone 
resorption. Their acidophilic cytoplasm is a result of the presence of lysosomal enzymes . 
OC precursors merge to form a multinucleated cell; the size of these cells permits activity on 
a large area of bone which is also enhanced by the mffled border, which appears only after 
the cell is attached to bone. 
Bone resorption is initiated by the release of collagenase from osteoblasts, which fosters the 
removal of the nonmineralized organic matrix. This exposes bone and attracts the OC to 
the site for attachment; OCs are unable to attach to demineralized bone or osteoid 
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surfaces. 117 OG attach to RGD sequences in bone matrix proteins via av~3 integrin 
(vitronectin) receptors. This integrin probably has as its most important function the 
transmittal of matrix-derived signals to the OC, driving cytoskeletal organization. LLB As a 
result, it has been suggested that the av~3 integrin receptors may be a good point at which 
to inhibit osteoporosis. 119 The "matrix attachment" is rich with filamentous actin (F-actin) 
which protrude from the plasma membrane, and are known as podosomes. 12 It is not 
known whether the podosomal ring acts in recognition or as an attachment structure. 121 
This clear zone, or "sealing" zone of attachment, enables the OC to create an extracellular 
environment suitable for the resorption of mineral and organic constituents. Acid and 
proteolytic enzymes including an osteoclast-specific acidic cysteine proteinase, cathepsin K, 
and :MJvlPs, gelatinase B (1v1MP-9), interstitial collagenase (:MJvtP-1), and stromelysin (1111:P-
3) are secreted onto the bone surface. These factors degrade the bone surface which 
includes the major bone matrix protein, type I collagen. The minerals are removed from the 
bone by the action of hydrogen, utilizing an electrogenic proton pump at the ruffled border 
which maintains a pH of 4.5 with a HC0 3-/Q - exchange. Chloride ions travel through a 
ruffled membrane-residing anion channel towards the bone surface. Non-collagenous 
proteins that are removed from the bone include osteocalcin, osteonectin, osteopontin, bone 
sialoprotein, manix Gla protein, thrombospondin, biglycan and others. They also provide 
necessary signaling for bone remodeling and resorption, providing growth factors and 
signals for appropriate areas of bone growth and repair. 
Res orbed bone products are endocytosed by the OC and then released on the antiresorptive 
surface. 122 The cycle of bone resorption includes detachment of the OC and movement to 
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new sites of bone resorption. 123 Following degradation of the surface, it is processed by 
macrophages, creating a cement line. Finally, osteoblasts then enter to form new bone. 
Systemic Control of Bone Remodeling 
The systemic control of bone remodeling is mediated by numerous hormones, including 
vitamin D 3 (1, 25-dihydroxycholecalciferol), parathyroid hormone (PTH), sex hormones , and 
calcitonin; the localized control is regulated through nitric oxide (NO), prostaglandins, 
growth factors and cytokines. 124 Growth factors and cytokines include IL-1, TNFa, TNF~, 
TGFa, TGF~, IL-6, and IL-11. However, the majority of these systemic mediators are 
unnecessary for osteoclast development. Many of the receptors for these substances are 
found on the osteoblast which then interacts with the osteoclast. This is achieved by factors 
regulating bone remodeling which act by influencing local expression of RANK, RANKL 
and OPG, considered to be essential to the cytokine network 125•126' 127•128 For example, Jones 
et al. have shown that factors such as TNFa and ILl act to increase the development of 
osteoclasts however this is depend ent on RANKL/RANK expression. 1.29 On the other 
hand, osteoprogerin, or soluble RANK, blocks osteoclast development and induces 
apoptosis. Osteoclast development is also blocked by estrogen, bone growth factors, bFGF, 
TGF~, and related bone morphogenic proteins, and certain other cytokines, IFN y, IL-4, IL-
10, and IL-18. 
20 
RANK/ RANKL Interactions 
Receptor activator of NFKB (RANK) and RANK ligand (RANKL), are two key proteins 
responsible for osteoclast formation and function. 130 RANK, a type I transmembrane 
Stromal CelllOsteoblast 
Macrophage 
Ollteocl•t 
Bone 
Figure 2. RANKL expressed on the preosteoblastic/ stromal cells binds to RANK on 
preosteoclastic cells. M-CSF, which binds to its receptor, c-Fms on the preosteoclastic cells 
are also important for osteoclastogenesis. RANKL is important for fusion of cells into 
multinucleated cells and survival of osteoclastic cells. OPG acts as a deco y receptor of 
· RANKL and prevents binding of RANKL to RANK. 
protein, and RANKL, a type II transmembrane protein, are members of the TNF family of 
cytokines which show high specificity, as reported by Lam et. al. 131 The amount of OPGL, 
the stimulator of osteoclastogenesis, versus the amount of OPG, the inhibitor of 
osteoclastogenesis, determines the direction of bone remodeling, by either addition or 
removal. The coupling of this pair is more than physiologic. In fact experiments that 
separated the two populations of cells exhibiting these proteins by means of a membrane, 
demonstrated that without the physical interaction, osteoclast formation was inhibited. 132 
Osteoclast formation is also inhibited by the addition of blocking antibodies to RANK, also 
known as soluble RANK. 133 This pair also plays a significant role in the development and 
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function of lymphoid tissue, and regulation of T cell and dentritic cell communications. 
Additionally, the role of these proteins includes the development of a lactating mammary 
gland during pregnanc y and the propagation of the mammalian species. Their interaction is 
so tightly knit together that removal of the RANK gene produces an exact phenocopy of 
RANKL-deficiem mice, hence the importance of the RANKL-RANK pathway. 134 This 
interaction can be seen in figure 2.135 These mice both exhibit lymph node agenesis, 
. . d 1 . d P ' h J l ( 1mpaire sp emc stmctures an eyers pate es. - J 
RANK, composed of 616 amino acids, is expressed by certain ·types of cells including 
progenitor and mature osteoclasts, activated T cells, and myloid derived dentritic cells.mm 
n ,
139
,
140 RANK activation, as reported by Jones et. al., causes signals to be sent into the cells 
by means of adapter proteins. 141 The intracellular portion of RANK has 383 amino acids, 
and is made up of three binding domains, I, II, and III, for tumour necrosis factor receptor 
associated factors (TRAFs). 142 
RANKL, a 317 amino acid polypeptide , is also known as osteoclast differentiation factor 
(ODF), 1NF related activation induc ed cytokine (TRANCE), and osteoprotegerin ligand 
(OPGL) and TNFSFl 1. RANKL has a molecular mass of 38 kd; its extracellular domains 
self-associate as a trimer. 14-' RANKL exists in both a soluble and membrane bound state; 
cleavage by metalloprotease-disintegrin TNF-a convertase (TACE) from the cell surface 
creates the soluble state. 1H RANKL, both produced by and residing on osteoblasts, acts on 
RANK, present on mature osteoclasts and their precursors, to promote osteoclast 
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. h h . d . f . . 1 d. F 145 146 Th. maturation t roug mcrease expression o certam genes, me u mg c- os. ' is 
increased expression occurs via intracellular signaling cascades that involve c-Jun, NF-KB, 
and serine/threonine kinase Akt/PKB pathways. Thus, the interaction between the 
osteoblast and osteoclast precursor results in the differentiation of a fully functional 
osteoclast. The importance of OPGL is undeniable in the formation of osteoclasts given 
that OPGL knockout mice lack marrow space and die of starvation because of impaired 
tooth eruption. 147 OPGL antibody added to culture inhibited osteoclast formation by 60-
70% in bacteria stimulated splenocyte culture. 148 RANKL thus causes those M-CSF 
stimulated precursors to commit to the osteoclast phenotype. 149 
Activator 
Osteoprotegerin ligand (OPGL) or 
Osteoclast differentiation factor (ODF) or 
Receptor activator of NFKB ligand 
(RANKL) or 
·1NF-relat ed activation induced 
cytokine (TRANCE) 
Inhibitor 
Osteoprotegerin (OPG , decoy receptor ) 
or 
Osteoclastogenesis inhibitory factor 
(OOF) or 
Osteoclast binding factor (OBF) or 
Source 
Stromal cells, 
osteoblasts, T cells 
RANKL, soluble and 
membrane bound, is also 
produced by activated 
ffi4 +and ms+ T 
cells.150' 151 In vivo, T cells 
1NF receptor- related molecule-1 (TRl) or 
Follicular dendritic cell-derived 
Receptor-1 (FDCR-1) 
Recepto r 
Receptor activator of NFKB (RANK) or 
Osteoprotegerin ligand receptor 
(OPGLR) or 
Osteoclast differentiation factor 
receptor (ODFR) 
Osteoclast 
precur sors, matur e 
osteoclasts, 
chondrocytes, 
dendritic cells 
are important mediators of 
bone loss by means of 
production of RANKL. 152 
This action is via indirect 
Table 1. Names of cytokine-receptor regulators and direct means. This 
occurs indirectly given that T cells promote bone resorption by expression of 
proinflammatoiycytokines that mediate RANKL expression in non-T cells.152 Although, in 
chronic systemic T cell activation, including autoimmune diseases, viral infections or local 
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inflammation, T cells are recruited and then actively engage in bone remodeling through 
direct RANKL production. 152 Jones et al. also inf erred that since mice lacking T cells still 
display normal bone cavities and tooth eruption, T cells are not likely necessary for normal 
bone homeostasis . It has also been found that T cell derived RANKL contributes to 
alveolar bone resorption and tooth loss in an animal model mimicking human periodontal 
disease. Inhibiting RANKL completel y prevents this alveolar bone loss. This can be 
achieved utilizing osteoprotegerin (OPG) which is produced by osteoblasts. 153 OPG binds 
to its congnate lignand, RANKL and prevents binding to RANK therefore inhibiting 
RANKL-mediated osteoclast maturation. 154 Thus, the osteoblast controls osteoclasts though 
the balance of OPG and RANKL. Although RANKL is present in various tissues, 
osteoclast development only occurs in bone thereby suggesting that another factor may act 
in conjunction with RANK and RANKL to limit their development in bone. 152 
Although T cells also exhibit this negative effect on bone loss once they are activated, they 
too are controlled to limit detectable bone loss with short-term activation. 155 Interferon 
gamma blocks RANKL activated osteoclast differentiation in vitro and prevents 
uncontrolled bone loss. Recently Takayanagi et al. have proposed a feedback mechanism 
found on osteoclasts for self regulation through the production of interferon-~ by means of 
the transc1iption factor c-Fos. 156 They propose that the protein is secreted from osteoclasts 
and then acts on itself, and on neighboring cells. Receptor binding causes a decrease inc-
Fos levels thereby inhibiting osteoclast differentiation. Although interferon-~ has been 
primarily known for its role in cellular responses to viruses, this new found role fits well into 
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the common lineage of osteoclasts and some of the immune cells; their interaction is thus 
very plausible. 157 
The receptors for RANKL include RANK and osteoprotegerin (0PG) and belong to the 
1NFR family. 0PG, the "protector of the bone," is also known as osteoclast binding factor 
(0BF), osteoclastogenesis inhibitory factor (0OF), 158 1NF receptor-related molecule-1 
(TRl), 159 and follicular dendritic cell-derived receptor-1 (FDCR-1) .160 The term endorsed by 
the American Society for Bone and Mineral Research Committee, is osteoprotegerin 
(0PG). 161 This molecule is an essential paracrine mediator of bone metabolism and immune 
system function. 0PG, a soluble decoy receptor that binds to both membrane-associated 
and soluble versions of RANKL, prevents the activation of RANK. 0PG lacks a 
transmembrane domain thus illustrating that it is released as a factor that acts to modulate 
osteoclast fonnation in an autocrine or paracrine fashion. Therefore, 0PG prevents 
activation and maturation of osteoclasts, 162.163 and is thus a potent inhibitor of osteoclast 
differentiation. Its addition to culture, in a concentration as low as lng/ ml causes a 50% 
inhibition of osteoclastogenesis. i64 
Following post-translational modifications , 0PG is secreted as a 110 kDa homodimer from 
a variety of tissues. These tissues include the cardiovascular system encompassing the heart, 
arteries and veins, the lungs, kidney, intestine, bone, hematopoietic and immune cells.163•165•166 
Downregulation of 0PG occurs with vitamin D 3, cyclosporine A, parathyroid hormone, 
prostaglandin E2, fibroblast growth factor, and glucocorticoids and these are therefore bone 
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resorbin g factors; conversely, cytokines, including IL-18, transforming growth factor (TGF)-
~' bone morphogenic proteins, steroid hormones, and Ca2+ and cause upregulation of OPG 
and are thus bone forming factors .·161,L68,169,L7o,111,m,11J,L14,1 s,116,1n,L1s,119,Lso,1s1,Ls2 Functionally, 
OPG prevents osteoclast activation and osteopenia in almost all model systems of osteoclast 
mediated bone loss. 152 Its binding maintains the balance of available RANKL and therefore 
ensures correct bone levels. In the bod y it is the ratio of OPG to OPGL which produc es 
the effect on bone, not the individual level of either OPG or OPGL. 
There has been some research compl eted with respect to OPG levels and diabetes. One 
stud y on OPG levels and mortality in elderly women with diabetes found OPG levels to be 
30% higher in women with diabet es than those without diabetes. 183 Another stud y on OPG 
levels in men with coron ary artery disease found that OPG levels were positi vely correl ated 
with age and were higher in men with diabetes mellitus. 184 Although numerous hypotheses 
were presented as to the cause of the higher levels of OPG in diabetics this is still open to 
debate. 
OPG also acts on TRAIL , anoth er TNF -related ligand which induc es apoptosis in cells with 
death dom ain expressing receptors. tss,186 OPG binds with TRAIL and thereby inhibits 
TRAIL-induced apoptosis. L87 Likewise , TRAIL inhibits the ability of OPG to block 
osteoclast action. In the final analysis, TRAIL is not considered to be involved in 
osteoclastogenesis. 
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Therapeutically, OPG would likely not be feasible as direct treatment to limit bone loss 
according to Rodan et al.188 Not only is it a large protein but it requires large doses, 
potentially causes immune responses and acts in organs other than only bone. It would 
seem more productive to research delivery by bone cells, utilizing gene therapy, which would 
then act locally. Given our current knowledge it would seem advisable that efforts to 
control bone destmction be mediated through RANKL inhibition. 189 Possible points of 
intervention include production of RANKL, interaction of RANKL with RANK, RANK 
signaling through Jun NH 2-terminal kinase GNK) and NF-KB pathways and through TNF 
receptor-associated factor (TRAF) adapter molecules. 188 Future study is also necessary on 
differences between soluble and membrane bound RANKL, the function of 
RANKL/RANK in the immune system, and T cell mediated bone loss and inhibition of 
osteoclastogenesis. 189 
Vitamin D3 
la,25-dihydroxycholecalciferol (1,25-(OH),D 3) is the major pharmacologicall y active 
metabolite of vitamin D3 and engages a critical role with calcium homeostasis. It is primarily 
the interactions between 1,25- (OH), D 3 and PTH that govern calcium levels.190 This 
environmentally derived steroid hormon e is absorbed from food and is then converted via 
three primary methods: by sunlight in the skin, in the liver, and terminally converted in the 
kidney. Its primary site of action is the intestine and bone. It promotes calcium resorption 
in the intestine and increases OB activity in the bone. In vivo, it has been shown to 
stimulate bone resorption in both intact and parathyroidectomized animals.191•192 Further 
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study in vivo is hindered by the lack of specific markers on OCs and their precursors which 
allow them to be identified. 190 In vitro, it has been shown to increase bone resorption in the 
mouse and rat.193 Primarily, its effect appears to be increasing OC activity, not necessarily 
increasing OC numbers. 19., Other researchers, however, have found OC formation in vitro 
and associated activity has been shown to increase with vitamin D).193 .194,195 In culture, the 
addition of 1,25 ( OH) 2D 3 and dexamethasone in co-culture encouraged a greater OC 
formation response; the role of vitamin D ., however remains controversial. 196 In diabetic 
type II patients, it has been noted that poor glycemic control impairs the responses of 
osteoblasts and osteoclasts to 1,25(0H) 2D/ 97 Another study which injected vitamin D., in 
diabetic and control rats found that it did not affect osteoblast numbers or the amount of 
osteoid in trabecular bone and as a result concluded that this treatment method cannot be 
expected to reverse diabetic osteopenia. 198 
In the past, vitamin D 3 was believed to directly act on OC precursors by increasing their 
differentiation; it is now assumed to function indirectly by increasing expression of RANKL 
on stromal cells and/ or OBs. 199 OCs do not possess the vitamin D receptor (VDR)200 and as 
such it would seem improbable that there is a direct effect on OCs. In fact, in isolated OC 
systems, no reported effects of 1,25(0H) 2D 3 have been seen, however in co-culture with 
OBs the response to vitamin D .i has been an increase in resorption. 194 Furthermore, OBs 
have been shown to express the VDR 20 1 and respond to vitamin D .i by the production of IL-
1 and IL-6.202 The presence of these VDR receptors on the monocyte-macrophage family 
and numerous lymphoid cell lines suggest that vitamin D 3 may also stimulate OC 
recruitment from hematopoietic precursors. 1 3 Further analysis is required on the 
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biochemical pathway that leads to increased activity of OG following exposure to 1,25-
( Of--I) 2D 3. 
Parathyroid Honnone 
Parathyroid hormone (PTH), which is produced in the parathyroid glands, targets the kidney 
and bone, where it promotes increased bone resorption. PTH acts to target OBs and some 
stromal cells which produce RANKL.204 Thorough studies on PTH demonstrate two time-
dependent effects: intermittent administration of parathyroid hormone has anabolic effects 
on bone 2 5 whereas · constant high levels of PTH increase bone resorption. This effect on 
bone formation can be explained by a decrease in the number of OBs undergoing apoptosis 
with the reduced or intermittant levels of PTH. 206 
In diabetics it has been noted that there is low bone turnover caused by either impaired 
secretion of PTH or refractoriness of osteoblasts to PTH. 207 In their findings these 
researchers report that the reduced PTH secretion may be responsible for the low bone 
turnover in hemodialyzed patients with diabetes. 
Macrophage Colony Stimulating Factor 
One of the growth factors necessary for proliferation, differentiation, and survival of 
hemopoietic cells of the monocyte- macrophage lineage into the early OC pathway is 
macrophage colony-stimulating factor (M-CSF).208 M-CSF acts through its receptor, c-fms, a 
receptor tyrosine kinase, which has been shown to be present on OG and their precursors, 
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but not in osteoblastic cells.2°9 This receptor is expressed at many different stages in OC 
development and acts as a survival factor in mature OCs. Research has shown that M-CSF 
is necessary for bone marrow-derived macrophages during the G 1 phas e to guarantee cell 
survival and entry into the S phase, and then is no longer needed once the cell is in S 
phase. 210 M-CSF acts as a costimulator for OPGL, which encourages fusion of OC 
precursors into multinucleat ed cells that can resorb bone. rn '212 Its addition in its soluble 
form enhances the generation of OCs by RANKL. Lees et al. demonstrated that cultures 
with the addition of MCSF show an increase in resorptive activity which appears to be 
related to the increased size of M-CSF-cultured OCs. 213 Their research also shows that the 
effect of M-CSF on OC size and resorption functioned independentl y of factors related to 
cell density. Another study found that the lack of M-CSF produced no osteoclasts, even 
with media including vitamin D. 214 It has also been demonstrated that mice which do not 
produce the MCSF or RANKL cytokines have a phenotype which displays a failure of tooth 
emption due to a lack of osteoclast formation .215'216 At high doses however, its action is 
inhibitory to osteoclastogenesis. 217 Given this information, M-CSF plays a valuable role in 
OC cultures. 
Lipopolysaccharide 
One of the first bacterial components shown to induce bone resorption in vitro was 
endotoxin, a complex of lipopolysaccharide (LPS) and 
proteins. 21s,219,22 -~21,222,m,224,22s,226, 21,22s,~29,n ,n 1,m This is also seen dentall y with alveolar bone 
loss similar to periodontitis, after systemic injection of LPS by osteoclastogenic action via 
the p55 1NF receptor .233 Despite the fact that LPS is known to induce bone resorption, 
little is known regarding its mechanism of action. Numerous studies by Sismey-Durrant and 
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Hopps, 231 Ueda and coworkers, 234 and others 235 have shown that LPS does not have a direct 
effect on the OC. It has also been shown that the addition of LPS does not induce OC 
differentiation in marrow stromal cell cultures in the absence of OBs. 236 It is known that 
LPS causes certain cell populations to manufacture cytokines and eicosanoids; 237 it also 
d . cl 1 . f . 1 cl. IL ?JS 239 IL 6 "40 )4 l 1 irects OBs to pro uce osteo ytic actors me u mg -1,- ' - ,- ,- granu ocyte-
h 1 . 1 . f "4} RANKL "43 1NF 741 1 cl. E2 244 d macrop age co ony stimu atmg actor,- - ,- -a,- - prostag an m , an 
nitric oxide. 245·246'247·248 Besides contributing to bone resorption, LPS has also been shown to 
inhibit collagen and noncollagenous protein synthesis. 249'250 As a result of these discoveries, 
it seems most logical to inf er that LPS acts to induce bone resorption indirectly by acting on 
OBs to produce factors which recmit and activate OCs. 251 
Recently, however, some experiments re-examined these inflammatory mediators and LPS 
and have found activation of OCs directly, independent of the RANK/RANKL pathway.252 
Observation though experimentation has shown that LPS reduces the expression of the 
RANK and MCSF receptor, both found on the osteoclast, yet stimulates osteoclastogenesis 
via TNF-a.253 This theory is further supported in that bone resorption induced by LPS is 
inhibited by cyclo-oxygenase inhibitor, indomethacin, or with anti-IL-1 antisemm/ 40 and 
selective inhibitors of the arachidonate-oxidizing enzyme 5-lipoxygenase, 254 which blocks 
OC mediated bone resorption in vivo. 255 It has also been shown by Jiang et al. that 
Parphyrormnas gj,ngj,7.aiis, nd E scherid1ia cdi LPS induce osteoclastic cell formation from murine 
leukocytes in the absence of OBs. 256 These observations were based on experiments 
showing that bacteria or LPS directly stimulated the generation of TRAP positive cells, 
which also expressed RANK, without the co-culture of OBs. Many questions still abound in 
this area of bone regulatory molecules , including LPS, according to Nair et al.257 The results 
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of these experiments point to the 
possibility that bacteria could affect 
bone resorption indep endentl y of 
OBs and that a variety of cells may 
be involved in both inflammatory 
and physiol?gic bone resorpti on.256 
Finally, LPS is one of many inducers 
of bone resorption , other s are 
outlined on Table 2.251 Futur e areas 
of study on LPS induced bon e 
resorption include: which cell 
population do they bind to, what are 
the details surrounding receptor , 
post-receptor events, and is the 
action direct or indirect? 
Mediator 
Circulating factors 
Parathyroid hormone 
1,25-dihydrm..7 vitamin D3 
Calcitonin 
IL-6 and other circulating cyrokine 
Estradiol and othe r steroid hormones 
Local factors 
Prostaglandins 
Leukotrienes 
Proinflammatoryc ytokines (IL-1, IL-6, TNF) 
Growth factors 
Bacter ial prod ucts 
LPSs 
Teichoic acids 
Lipid A-associated protein s 
Porms 
Cpn6 0 of A . A ainomp:tem:onitans and E. coli 
Capstatin of A. A aino~tans 
PMT 
B. bronchi septica DNT 
Cell wall components of man y bacteria 
Surface-as ociated protein s of A . aainorny:etem:JJmiJ.ans, 
P. rJ:rgi:u:ilis, E. conrxlens, Staphjwxcus 
aureus, and Staphykxcca/5 epidemidis 
Capsular polysaccharide of A . aainom;m:e,rrornitans 
3 2- and 60-kDa surf ace-associated proteins of 
S mphylwxcus aure,,15 
43-kDa P. gi:ngi:udis fr mbrial protein 
Table 2. Mediators of bone remode ling 
Targets to Inhibit Osteoclastic Bone Loss 
Numerous targets are available to limit bon e resorption as outlined by Rodan et al. 258 A 
possible target on the osteoclast is cathepsin K, a lysosomal cysteine prot einase, which could 
be inhibited. The presentation of the av~3 integrin receptor could also act as a point of 
intervention; this integrin is also found in budding blood vessels and leukocytes. This has 
been experimentally shown to inhibit bone resorption in rats, with injection of disintegrins , 
echistatin, or kistrin, after stimulation by estrogen deficiency or parathyroid hormone. 259 
Further exploration would be required to determine its viability. The H +-adenosine 
32 
triphosphatase (H+-ATPase) acts to create the acidic environment necessary for resorption; 
inhibitors like bafilomycin, have been demonstrated to inhibit resorption both in vitro and in 
vivo.160 By no means is this list exhaustive but rather merely some of the possible methods 
of interacting and limiting bone resorption. Further investigation will no doubt yield more 
possibilities and open new doors. 
Apoptosis 
At this point, little is known regarding termination of resorption, although some possible 
theories abound. In the past decade cell death has been the subject of much study. Two 
types of cell death are typically described, necrosis and apoptosis . Apoptosis has a 
recognizable sequence of events leading to cell death and is controlled by intracellular means 
with the option of extracellular control through receptors from external factors .261 OC 
control is of great importance especially considering the speed with which OCs function, 
requiring only a fraction of the time required by OBs to replace resorbed bone. The 
consequence of uncontrolled OCs cannot be overstated. For this reason, the absence of an 
interaction between RANK and RANKL causes apoptosis to ensue and leads to death of the 
OC lineage cells.262 The study of the OC is often clouded by the fact that it is difficult to 
isolate large numbers of this cell and that pure populations are even more difficult to attain . 
In vitro, OCs have been shown to be susceptible to apoptosis; this is reduced by inclusion of 
IL-1 and M-CSF in the culture media, which has been assumed to suppress 
apoptosis .263•264·265•266•267 It has also been noted that OCs may die by apoptosis when deprived 
of attachment to their normal substrate, termed anoikis, this however still needs to be 
established. 268 
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Generally, factors stimulating bone resorption inhibit OC apoptosis and factors that inhibit 
bone resorption promote OC apoptosis. 264 Additionally, certain dmgs are known to 
stimulate OC apoptosis, including estrogen, aminobisphosphonates, etoposide, 1NF a, and 
dexamethasone; this allows a degree of success in the treatment of bone disorders. 269 
Besides the action of P1H reducing apoptosis, the protection of osteoblastic and osteocytic 
cells from in vitro induced apoptosis has also been achieved with bisphosphonates or 
calcitonin. 269 This occurs at nanomolar concentrations, far lower than would be required to 
decrease bone resorption. Treatment with vitamin D 3 has shown that OC numbers decrease 
after vitamin D 3 application ;27 other research has shown that OC apoptosis tends to follow 
the OC activity.271 Given the advances in this area, this will hopefully play an important role 
in OC and OB control in the coming years . 
TRAP Staining 
This staining method utilizes acid phosphatase which hydrolyzes the substrate napthol AS-
BI phosphoric acid, which then couples with a diazo dye.272 The dye then precipitates at the 
site of enzyme activity. This staining method is typically used for detection of hairy cell 
leukemia. Since osteoclasts express tartrate resistant acid phosphatase, they are also stained, 
as are some osteoblasts and osteocytes, which also express TRAP activity in vivo. 273 As 
such, it is imperative that identification of OCs be undertaken considering morphological 
characteristics such as multinuclearity in addition to TRAP staining. As well, TRAP 
expression is limited to OCs of the marrow, irrespective of whether these cells are 
undergoing apoptosis or not. 274 This aspect of this staining technique must therefore be 
considered in that stained cells may not be functional, but apoptotic and skew the number of 
observed OCs higher. 
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Materials and Methods - Part I - Diabetes Mellitus 
Mice 
The diabetic mice, BKS-cg-m+/ +, and their controls were purchased from Jackson Labs. 
Mice were sacrificed by a lethal injection of anesthetic. The femur and tibia of the hind 
limbs were removed under sterile conditions. The metaphyseal ends of the bones were 
removed and the marrow cavities rinsed with "complete" media. After filtering, the cells 
were counted and diluted to the appropriate concentration. The procedures were approved 
by the Institutional Animal Care and Use Committee at Boston University. 
Bacteria 
Lipopolysaccharide (LPS) isolated from E scheJidJ-ia cdi O 111 :B4 was purchased from List 
Biological Laboratories in a 5.0mg vial. The LPS was diluted utilizing phosphate-buffered 
saline (PBS) to the desired concentrations. 
Porphyronvnas gj,ngj,mlis was provided by biological core from the oral biology department. 
Marrow Stromal C.ell Cultures - Osteoclasts 
Freshly isolated marrow stromal cells were plated on 24 well Costar plates at 10x106 cells/ ml 
in 0.5ml volumes of media consisting of 1 % penicillin/ streptomycin, 10% fetal bovine 
semm (FBS) into a-minimal essential medium ( a- lvlEM) with monocyte colony stimulating 
factor (MCSF) at 20ng/ ml and 1,25-dihydroxycholecalciferol (1,25-(OH) 2D 3) at lOnM. 
Media changes occurred every 3 days. Plates were cultured for 21 days at 5% CO 2 and 95% 
humidified air and stimulated with varying concentrations of LPS. Cells were then stained 
for tartrate- resistant acid phosphatase (TRAP). Each well was examined with light 
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microscopy at 20x magnification and TRAP-positive cells containing greater than three 
nuclei were identified as osteoclast-like cells. 
Marrow Stromal Cell Cultures - Mineralizing Matrix 
Freshly isolated marrow stromal cells were plated on a 6 well Falcon plates at 8.3x106 
cells/ ml in 3ml volumes of media consisting of 1 % penicillin/ streptomycin, 10% fetal 
bovine serum (FBS) into a-minimal essential medium ( a- JvIEM). The media was changed 
on day 3. From day 7 onward, additional constituents were included in the media: 
dexamethasone at 10-8M, ascorbic acid at SOp.g/ ml, and ~-glycerophosphate at 10mmol. 
Media changes then commenced every 2 days. Cells were then stained for calcium by von 
Kossa's method on day 21. The total area of mineralized bone-like nodule were quantified 
using Image Pro software. 
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Protocols 
Protocol for Glucose Testing 
Materials: 
• mouse tube 
• tongue dispensor 
• · alcohol 
• razor blade 
• Accu-Chek Advantage O:mifort Curve test strips (Hoffman-LaRoche Ltd., Basel, 
Switzerland) 
• Advantage Comfort Curve Blood Glucose Monitor (Boehringer Mannheim 
Corporation , Indianapolis, Indiana) 
Method: 
1. At 8-12 weeks of age the blood glucose level of the mice is checked. Mice are placed in 
the mouse tube and the alcohol wipe is used to disinfect the tip of the tail. A very small 
portion of the tip of the tail is cut off thereb y allowing blood to be squeezed out using digital 
pressure along the length of the tail. Readings greater than 250mg/ dl are considered to 
reflect evidence of the diabetic condition. 
2. Mice which demonstrate high glucose levels ( >250mg/ dl) will be retested in 5-7 days. 
3. Mice which do not demonstrate high glucose levels will be retested at 24, 48, 72 and 96 
hours. Mice which then demonstrate this elevated glucose level will then be retested in 5-7 
days. 
4. Any mice that do not have an elevated glucose level and remain elevated are excluded 
from the experiment. 
5. Following testing, digital pressure is applied at the distal most extremity of the tail to 
accelerate clotting. 
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Protocol for Bone Marrow Cell Isolation 
Materials: 
• anesthetic 
• 80% ketamine ( lO0mg/ ml) 
• 20% xylazine (20mg/ ml) 
• 70% alcohol 
• cooler with ice 
• razor blade 
• sterile scissors, forceps,# 15 scalpel blade and handle 
• 50mL Falcon tubes (Fisher# 05-539-6) 
• 18 gauge needle (B-D # 305196) 
• 30 gauge needle (B-D # 305106) 
• lOmL syringe (Fisher 148232A) 
• 70µm nylon strainer (Falcon# 2350) 
• complete media 
• 500ml aminimal essential media (Gibco # 12571, lot# 1152838) 
• 50ml fetal bovine serum (Sigma# F2442, lot# 30K8420) 
• 5.5ml penicillin-streptomycin-glutamine (Gibco # 10378-016, lot# 1024689) 
• 2.22ml Fungizone (Gibco # 15290-018, lot # 3076059) 
• PBS (Gibco # 20012-027, lot# 114451) 
Method: 
1. E uthanize mice by deep anesthetization by injecting mice with 1 ~Ll mixed anesthetic. This 
procedure is completed according to the IACUC approved protocol and in a manner 
consistent with federal and institutional guidelines. 
2. External posterior surfaces are rinsed with 70% alcohol. 
3. The skin and fur over the hind limbs is removed. 
4. The hind limbs are then removed and are all placed in ice cold PBS. The remainder of 
this protocol is to be completed under the fume hood. 
5. The tissue is removed from all the femurs and tibias, which are then placed in ice cold 
PBS. 
6. Metaphyseal ends of the femur and tibia are removed to allow access to the marrow 
cavity. 
7. Marrow cavity contents are flushed out using a 30-guage needle attached to a lOmL 
syringe containing "complete" media, using approximate ly 5ml per posterior limb. 
8. Following the flushing, the cell suspension is further dissociated by drawing media 4-6 
times through an 18-guage needle. 
9. Filter the suspension through the Falcon strainer into a fresh falcon tube. 
10. :Half of the cells are utilized for osteoclast formation and half are utilized for 
mineralizing nodule formation. 
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Protocol for Counting Cells using Hemacytometer 
Materials: 
■ 
■ 
■ 
■ 
■ 
■ 
■ 
hemacytometer 
"complete" media 
■ see description under 'Protocol for Bone Marrow Cell Isolation' 
filt:ered cells in "complete" media 
glass cover slips 
pipette 
. . 
pipette tips 
large eppendorf tubes 
Method: ( completed under fume hood): 
1. Add 380~d "complete" media to a large eppendorf tube. 
2. Ensure the filtered cells are evenly suspended by gently turning the falcon tube end over 
end . 
3. Transfer 20µ1 of the mixed, filtered media into the eppendorf tube. Ensure all the cells 
are removed by rinsing the pipet tip with media from the eppendorf tube. 
4. Place a cover slip on the hemacytometer 
5. Taking a new pi pet tip, agitate the media in the eppendorf tube to disperse the cells 
evenly. Now remove a small amount of media from the eppendorf and dispense it into the 
channel on the hemacytometer. 
6. Using a l0x magnification, total the cells found on the grids located at the four comers of 
the central grid and find the average. 
7. Multiply the average by 20, and then by 104 . This is the number of cells per milliliter in 
the falcon tube. 
Average Number of Cells Formula: 
(Average number of cells on hemacytometer) x (Dilution factor) x (104) = Number of cells 
per milliliter 
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Protocol for Osteoclast Formation 
Materials: 
• "complete" media 
• see description under 'Protocol for Bone Marrow Cell Isolation' 
• "osteoclastogenic" media 
• · "complete" media 
• monocyte colony stimulating factor at 20ng/ ml (R&D # 416-ML) 
• 1,25-dihydroxycholecalciferol (1,25-(OH) 2D 3) at 10nM 
• lipopolysaccharide (List# 201) 
• 24 well plates (Costar# 3524) 
Method: ( completed under fume hood): 
1. Count cells with a hemacytometer and plate 5x106 cells per well (5 million cells per well) 
at 10x106 cells per milliliter (10 million cells per ml) on 24 well plates at 0.5ml per well using 
"complete media." Culture at 37°C in 95% .humidified air and 5% CO 2• 
2. Add to the entire culture, 1,25-dihydroxycholecalciferol (1,25-(OH) 2D 3) at 10nM and 
MCSF at 20ng/ ml. 
3. Every 3 days, the old medium is replaced with 0.4ml fresh medium/well. 
4. At day 21, the cells are fixed and stained for tartrate-resistant acid phosphatase (TRAP) 
act1v1ty. 
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Protocol for Mineralizing Matrix (Nodule) Fonnation 
Materials: 
• "complete" media 
• see description under 'Protocol for Bone Marrow Cell Isolation' 
• "osteogenic" media 
• "complete" media (see Protocol for Bone Marrow Cell Isolation) 
• dexamethasone at 10-8M final concentration (Sigma# D-8893) 
• ascorbic acid at 50~tg/ ml final concentration (Sigma# A-7506) 
• ~-glycerophosphate at 10mmol final concentration (Sigma# G-6251) 
• 6 well plates (Falcon # 3846) 
Method: ( completed under fume hood): 
1. Count cells with a hemacytometer and plate 2.5x107 cells per well (25 million cells per 
well) at 8.3x106 cells per milliliter (8.3 million cells per ml) on 6 well plates at 3 ml per 
well using "complete media." Culture at 37°C in 95% humidified air and 5% CO2• 
2. On day 4, half of the media is removed from the culture and replaced with fresh 
" 1 " d' comp ete me 1a. 
3. On day 7, all media is removed and the cells are fed with "osteogenic" media. 
4. Change media every two days until fixing and staining at 21 days of culture. 
Protocol for Porphyromonas gingiwlis injection 
Materials: 
• alcohol wipes 
• anesthetic 
• see description under 'Protocol for Bone Marrow Cell Isolation' 
Method: 
1. E uthanize mice by deep anesthetization by injecting mice with 1 ~tl anesthetic mixture. 
This procedure is completed according to the IACUC approved protocol and in a manner 
consistent with federal and institutional guidelines . 
2. Using an alcohol swab, disinfect the area on the head between the eyes and ears. 
3. Inject 2x109 I 50µ1 P. gj,ngimlis subcutaneously, with insertion between the ears and site of 
delivery between the eyes and ears. 
41 
Protocol for Tartrate Resistant Acid Phosphatase (Trap) Staining 
Materials: 
• 10% Paraformaldehyde 
• l0MNaOH 
• lMHO.., 
• 0.2M Tris Maleate Buffer pH 5.0 
• Dissolve 47.44g tris maleate (Sigma# T-3128) in 800ml distilled water. 
• To adjust the pH add 10ml 10M NaOH and then lM HO dropwise to 
pH5.0. 
• 10% Mn0 2 (Sigma# M-3634) 
• Hematoxylin 
• Filter into a 50ml falcon tube using paper towel as filter. 
• 70% Alcohol 
• Dissolve 9ml of distilled water in 21ml of alcohol 
• Acid alcohol 
• Dissolve 0.25ml of lM HO in 24.75ml of 70% alcohol. 
• Ammonia alcohol 
• Dissolve 0.25ml of ~OH in 24.75ml of distilled H 20. 
• TRAP solution: 
• Add in sequence: 
• Distilled water 
• 0.2M Tris Maleate Buffer (pH 5.0) 
• Naphthol AS-MX phosphate (Sigma N-4875) 
• N,N-Dimethylformamide (Sigma D-8654) 
• Fast Red Violet LB salt (Sigma F-3381) 
• Sodium Tartrate (Sigma S-8640) 
• 10% Mn0 2 (Sigma M-3634) 
23.6 ml 
25 ml 
25 mg 
1.4 ml 
50mg 
0.1 g 
2 drops 
• Shake vigorously, filter (using 60ml B-D syringe (309653) and Gas 
Osmonics filter (DGA0202550)). Use solution immediately. 
Method: 
1. Remove all existing medium. 
2. Add ~200~Ll 10% paraformaldehyde per well to cover cells. 
3. Leave for 30 minutes. 
4. Remove all paraformaldehyde. 
5. Add 0.5ml TRAP solution per well and incubate at 37°C for 2 hours. Check staining 
under microscope after 30 minutes. 
6. Wash plate in a slow stream of distilled water for approximately 20 minutes. 
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7. Counterstain by adding approximately 200~d hemoxylin per well, and allowing the stain to 
function for 1 minute. 
8. Wash in nmning distilled water to remove hemoxylin. 
9. Add ~ 200~d acid alcohol per well for 30 seconds and remove. 
10. Add ~200pJ distilled per well for 30 seconds and remove. 
11. Add ~200~Ll ammonia water per well for 30 seconds and remove. 
12. A~d ~200µ1 distilled water per well for 30 seconds and remove. 
13. Add ~200µ1 80% alcohol per well for 10 seconds and remove. 
14. Add ~200~Ll 95% alcohol per well for 10 seconds and remove. 
15. Add ~200~Ll 100% alcohol per well for 10 seconds and remove. 
16. Add ~200~d 100% alcohol per well for 10 seconds and remove. 
17. Leave plates to dry. 
Protocol for Counting Osteoclasts 
The TRAP-positive cells with three or more nuclei are coLmted under the microscope at 20x. 
TRAP activity is denoted by red staining cells, with multiple green-stained nuclei. The 20x 
field of view fits 16.5 times across a well on a 24 well plate. In total, each well is coLmted at 
8 assigned field of views. The number of osteoclasts per field is averaged and then 
multiplied by the total number of field of views per well. 
Protocol for Mineralizing Matrix (Nodule) Staining 
Fix cultures with a 30 minute 1 % paraformaldehyde and stain for calcium by von Kossa's 
method. Freshly prepared 2% silver nitrate (20mg silver nitrate (Sigma S-8157) per ml of 
distilled water) is added to the plates (0.5ml/well), which are then incubated in the dark for 
10 minutes. Stop the reaction by rinsing thoroughly with distilled water and exposing to 
bright light for 10 minutes using two 60 Watt bulbs. 
Protocol for Quantifying the Mineralizing Matrix (Nodule) Area 
The total area of mineralized bone- like nodules is measured by capturing the microscopic 
image on a computer monitor. The total mineralized area is quantified using Image Pro 
software. 
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Results - Part I - Diabetes Mellitus 
1. Dose response of osteoclast formation 
Day 0: 
The osteoclast experiments were carried out to determine whether bacteria in the form of 
lipopolysaccharide could directly stimulate marrow stromal cells to form osteoclastic cell 
types and whether an injection with Porphyrormnas gj,ngi:udis prior to the harvesting of marrow 
stromal cells would affect the number of osteoclast cell types. Osteoclast cell types were 
identified by the presence of three or more nuclei and positive tartrate-resistant acid 
phosphatase (TRAP) staining. TRAP positive cells are formed in the presence of bacterial 
stimulation. Without a P.g. injection, stimulation of diabetic and control marrow stromal 
cells with lipopolysaccharide appeared to be dose dependent. As the concentration of 
lipopolysaccharide was increased from Ong/ ml to 9000ng/ ml there was an increase in 
osteoclast-like cells, with a decrease of cells at the top concentration. Although the diabetic 
marrow stromal cells appeared to usually exhibit slightly increased numbers of formed 
osteoclasts compared with control marrow stromal cells, the difference at all levels, except 
9000ng/ ml, was insignificant. In most experiments, without the addition of 
lipopolysaccharide, few osteoclast-like cells were formed. Typical osteoclast like cells from 
both the diabetic marrow and the control marrow can be seen in photomicrograph la and 
1 b respectively. 
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Chart 1 
Legend for Chart 1: 
This chart, representative of other similar experiments which were carried out, is the result 
of one experiment which used a total of 4 diabetic mice and 4 control mice, all between the 
ages of 8-12 weeks. Stromal cells were isolated from the bone marrow and cultured with 
"osteoclastogenic media." (For complete description see 'Protocol for Osteoclast 
Formation.') Vitamin D at 10nM and MCSF at 20ng/ml was included in the culture 
medium. There were a total of 24 wells of diabetic cells and 24 wells of control cells plated 
at 5 million cells per well on 24 well plates. The media was changed every 3 days and the 
cells were stained for TRAP activity and counterstained with hematoxylin after 21 days of 
culture. Under 20x power, a specific area of every well was counted for osteoclasts to 
determine the average number of osteoclasts in the entire well. The standard error was 
calculated to determine the size of the error bars. Statistical analysis using ANOVA, was 
applied to determine whether the means of the multiple groups were equal. Since the means 
were determined to be unequal, Scheffe's post-hoc comparison was used to determine the 
statistically significant difference in means. It was determined that at the highest level of 
stimulation, 9000ng/ ml, there was a statistically significant difference between the osteoclast 
numbers of the two groups, with a=0.05, denoted by the asterisk. 
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Photomicrograph la. Diabetic OCs Photomicrograph lb. Control OCs 
Legend for Photomicrograph 1a and lb. 
Diabetic (1 a) and control (1 b) mice marrow stromal cell cultures stimulated by LPS at 
3000ng/ ml seen under 20x magnification. The photomicrographs show multi.nucleated, 
TRAP positive osteoclast-like cells. These pictures were taken from a representative area. 
(For complete description see 'Protocol for Osteoclast Formation.') 
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Days 
This experiment matched the previoU5 experiment with the addition of an injection of P.& 5 
days prior to harvesting the marrow stromal cells. The results found were very similar to the 
previous experiment despite the additional insult of the P.g injection. Without the addition 
of lipopolysaccharide, there was very little osteoclast cell development in either control or 
diabetic marrow stromal cells. With logarithmic addition of lipopolysaccharide, the numbers 
of osteoclast-like cells increased to their maximum numbers, which again appeared with a 
stimulation of 3000ng/ ml. It is also noted that the range of osteoclast numbers produced 
between this experiment and the previous, with no P.g injection, were very similar and 
ranged from close to zero to slightly more than 7000 osteoclast-like cells per well. At 
concentrations above this level, the osteoclast numbers appeared to taper off. At no dose of 
LPS was there a significant difference between marrow stromal cells of the diabetic mouse 
versus the control mouse. Osteoclast-like cells can be seen in diabetic photomicrograph 2a 
and in control photomicrograph 26. 
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Dose Response of Db/Db and Control Osteoclast 
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Legend for Chart 2 
This chart, representative of another similar experiment which was carried out, is the result 
of one experiment which used a total of 4 diabetic mice and 4 control mice, all between the 
ages of 8-12 weeks. Mice in this experiment all received an injection of P.g. 5 days prior to 
marrow cell harvesting. Stromal cells were isolated from the bone marrow and cultured with 
"osteoclastogenic media." (For complete description see 'Protocol for Osteoclast 
Formation.') Vitamin D at 10nM and MCSF at 20ng/ml was included in the culture 
medium. There were a total of 23 wells of diabetic cells and 24 wells of control cells plated 
at 5 million cells per well on 24 well plates. The media was changed every 3 days and the 
cells were stained for TRAP activity and counterstained with hematoxylin after 21 days of 
culture. Under 20x power, a specific area of every well was counted for osteoclasts to 
determine the average number of osteoclasts in the entire well. The standard error was 
calculated to determine the size of the error bars. Statistical analysis using ANOVA, was 
applied to determine whether the means of the multiple groups were equal. It was 
determined that there was no statistically significant difference between the osteoclast 
numbers of the two groups at any level of LPS stimulation, with a=0.05. 
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Photomicrograph 2a. Diabetic OCs Photomicrograph 2b. Control OCs 
with 5 Day P.g. Injection with 5 Day P.g. Injection 
Legend for Photomicrograph 2a and 2b 
Diabetic (2a) and control (2b) mice marrow stromal cell cultures stimulated by LPS at 
3000ng/ ml seen under 20x magnification. The mice were injected with P.g. 5 days prior to 
harvesting marrow cells. The photomicrographs show multinucleated, TRAP positive 
osteoclast-like cells. These photomicrographs were taken from a representative area. (For 
complete description see 'Protocol for Osteoclast Formation.') 
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Day8 
This experiment modified the previous experiment by increasing the length of time between 
injection of P.g. and harvesting of marrow stromal cells from 5 days to 8 days. The results 
of this experiment appear similar to that of the previous two. Although there is increased 
variation between one group and its matching control, the ANOV A results indicate that 
there is no difference between the two groups at each concentration of LPS. As well, the 
overall trend of the two groups moves upward with increased osteoclast-like cells as the 
concentration of LPS is increased. One minor cliff erence that can be noted is the increase in 
osteoclast-like cells at the highest concentration of LPS, 9000ng/ ml, in both the control and 
diabetic groups whereas previous experiments illustrated a decrease in osteoclast-like cell 
numbers in both groups at this concentration. Overall, both groups in this experiment 
displayed much lower numbers of osteoclast-like cells when maximally expressed with 
approximately 800-900 cells per well. Typical osteoclast-like cells can be seen in 
photomicrograph 3a for the diabetic marrow and photomicrograph 3 b for the control 
marrow. 
50 
Dose Response ofDb/Db and Control Osteoclast 
Numbers at Various LPS Concentrations With a P.g. 
Injection on Day 8 (April 29, 2003) 
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Legend for Chart 3 
This chart is the result of one experiment which used a total of 4 diabetic mice and 4 control 
mice, all between the ages of 8-12 weeks. Mice in this experiment all received an injection of 
P.g. 8 days prior to marrow cell harvesting. Stromal cells were isolated from the bone 
marrow and cultured with "osteoclastogenic media ." (For complete description see 'Protocol 
for Osteoclast Formation.') Vitamin D at 10nM and MCSF at 20ng/ml was included in the 
culture medium. There were a total of 24 wells of diabetic cells and 24 wells of control cells 
plated at 5 million cells per well on 24 well plates. The media was changed every 3 days and 
the cells were stained for TRAP activity and counterstained with hematoxylin after 21 days 
of culture. Under 20x power, a specific area of every well was counted for osteoclasts to 
determine the average number of osteoclasts in the entire well. The standard error was 
calculated to determine the size of the error bars. Statistical analysis using ANOVA, was 
applied to determine whether the means of the multiple groups were equal. It was 
determined that there was no statistically significant difference between the osteoclast 
numbers of the two groups at any level of LPS stimulation, with a=0.05. 
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- . Photomicrograph 3a. Diabetic OCs Photomicrograph 3b. Control OCs 
with 8 Day P.g. Injection with 8 Day P.g. Injection 
Legend for Photomicrograph 3a and 3b 
Diabetic (3a) and control (3b) mice marrow stromal cell cultures stimulated by LPS at 
3000ng/ ml seen under 20x magnification. The mice were injected with P.g. 8 days prior to 
harvesting marrow cells. The photomicrographs show multinucleated, TRAP positive 
osteoclast-like cells. These photomicrographs were taken from a representative area. (For 
complete description see 'Protocol for Osteoclast Formation.') 
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DayU 
This experiment further increased the length of time between injection and removal of 
marrow stromal cells to a 12 day period. Similar results were found to previous variations of 
this experiment. Few osteoclast-like cells tended to be produced without the addition of 
LPS, but its inclusion at increasingly higher doses tended to cause the osteoclast-like cell 
numbers to increase as well. Where previous experiments illustrated the greatest numbers of 
osteoclasts at 3000 or 9000ng/ ml, this expe1~ment showed the greatest osteoclast expression 
at lO00ng/ ml LPS. Again, when comparin g the control and diabetic marro w stromal cells 
response statistically, the ANOV A results indicate that there is no statistical difference 
between the two groups. As in the experiment with an 8 day spread betwe en injection and 
harvesting, this experiment showed an overall reduction in osteoclast-like cell numbers, with 
a maximum number of osteoclast-like cells at approximately 2000 cells per well. The 
cliff erences between the two groups in this experiment is seen visually in photomicrograph 
4a, diabetic marrow stromal cells and photomicrograph 46, control marrow stromal cells. 
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Dose Response of Db/Db and Control Osteoclast 
Numbers at Various LPS Concentrations With a P.g. 
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Legend for Chart 4 
This chart is the result of one experiment which used a total of 4 diabetic mice and 4 control 
mice, all between the ages of 8-12 weeks. Mice in this experiment all received an injection of 
P.g. 12 days prior to marrow cell harvesting. Stromal cells were isolated from the bone 
marrow and cultured with "osteoclastogenic media." (For complete description see 'Protocol 
for Osteoclast Formation.') Vitamin D at 10nM and MCSF at 20ng/ml was included in the 
culture medium. There were a total of 24 wells of diabetic cells and 1 7 wells of control cells 
plated at 5 million cells per well on 24 well plates. The media was changed every 3 days and 
the cells were stained for TRAP activity and counterstained with hematoxylin after 21 days 
of culture. Under 20x power, a specific area of every well was counted for osteoclasts to 
determine the average number of osteoclasts in the entire well. The standard error was 
calculated to determine the size of the error bars. Statistical analysis using ANOV A was 
applied to determine whether the means of the multiple groups were equal. It was 
determined that there was no statistically significant difference between the osteoclast 
numbers of the two groups at any level of LPS stimulation, with a=0.05. 
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Legend for Photomicrograph 4a and 4b 
Photomicrograph 4b. Control OCs 
with Day 12 P.g. Injection 
Diabetic ( 4a) and control ( 4b) mice marrow stromal cell cultures stimulated by LPS at 
3000ng/ml seen under 20x magnification. The mice were injected with P.g. 12 days prior to 
harvesting marrow cells. The photomicrographs show multinucleated, TRAP positive 
osteoclast-like cells. These photomicrographs were taken from a representative area. (For 
complete description see 'Protocol for Osteoclast Formation.') 
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2. Time course of Osteoclast Fom1ation 
When the osteoclast formation is plotted comparing control and diabetic groups with no 
LPS stimulation and high dose LPS stimulation (9000ng/ ml), at 0, 5, 8 and 12 days, an 
interesting observation can be made. The addition of LPS to both control and diabetic 
groups on day O and 5 displayed a much higher number of osteoclasts than on day 8 and 12. 
Although the results on day O were not considered significant due to the lower number of 
osteoclasts in the control group with LPS stimulation, the results were considered 
significantly different on day 5, using Scheff e's post-hoc comp arison. Without the additon 
of LPS the number of osteoclasts were relatively constant over the course of the experiment. 
In the compa1~son of day 8 and 12 all four groups displayed similar numbers of osteoclasts. 
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Chart 5 
Time Course Comparing Diabetic and Control 
Osteoclast Numbers (March 26 and April 29, 2003) 
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Day 0 Day S Day 8 Day 12 stimulation 
Day (0, 5, 8, 12) 
Legend for Chart 5 
This chart is the result of two separate experiments which used a total of 16 diabetic mice 
and 16 control mice, all between the ages of 8-12 weeks. Mice in these experiments received 
either no injection, an injection of P.g. on either day 5, 8 or 12. Stromal cells were isolated 
from the bone marrow and cultured with "osteoclastogenic media." (For complete 
description see 'Protocol for Osteoclast Formation.') Vitamin D at 10nM and MCSF at 
20ng/ ml was included in the culture medium. There were a total of 9 5 wells of diabetic cells 
and 89 wells of control cells plated at 5 million cells per well on 24 well plates. The media 
was changed every 3 days and the cells were stained for TRAP activity and counterstained 
with hematoxylin after 21 days of culture. Under 20x power, a specific area of every well 
was counted for osteoclasts to determine the average number of osteoclasts in the entire 
well. The standard error was calculated to determine whether the size of the error bars . 
Statistical analysis using ANOVA was applied to determine whether the means of the 
multiple groups were equal. It was determined that there was a statistically significant 
difference between the osteoclast numbers of the two groups on day 5, with a=0.05 . 
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3. Nodule Formation 
The exploration of the differences in diabetic marrow stromal cells continued with 
experiments on bone nodule formation. These experiments attempted to ascertain whether 
a cliff erence exists between diabetic marrow cells and control marrow stromal cells in the 
formation of bone nodules. These experiments illustrated that between the three different 
points in time there tended to be a significant increase in bone nodule formation especially 
as time ensued between injection of P.g. and harvest of marrow stromal cells. Although both 
control and diabetic groups increased nodule formation with time, there was no statistical 
difference between the diabetic and control groups at either day O or day 8. Their 
comparison on day 5 yielded a statistically significant difference using Scheffe's post-hoc 
procedure. The appearance of a difference, although not statistically large, may be 
accounted for by the three-fold increase in variance in the diabetic group between day 5 and 
day 8. The sample size for these two days was also small, and a larger sample would likely 
have changed this observation from a large difference without significance to a large 
difference with significance. These differences can also be noted on the diabetic 
photomicrographs Sa, 6a, 7a, 8a and control photomicrographs Sb, 66, 76, 86 which both 
show 0, 5, 8, and 12 days respectively. 
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Legend for Chart 6 
This chart is the result of three separate experiments which used a total of 23 diabetic mice, 
and 22 control mice, all between the ages of 8-12 weeks. Stromal cells were isolated from 
the bone marrow and cultured with "complete media;" there were a total of 30 wells of 
diabetic cells on day 0, 12 wells of diabetic cells on day 5, 12 wells of diabetic cells on day 8, 
29 wells of control cells on day 0, 12 wells of control cells on day 5, and 12 wells of control 
wells on day 8. (For complete description see 'Protocol for Bone Marrow Cell Isolation.') 
The media was changed on day 4 and then changed to "osteogenic" media on day 7. (For 
complete description see 'Protocol for Mineralizing Matrix (Nodule) Formation .') The 
media was then changed every two days and the cells stained for nodule formation on day 21 
by von Kossa's method. Image Pro software was used to count the nodule formation to 
determine average area of growth per well. The standard error was calculated to determine 
the size of the error bars. Statistical analysis using ANOV A was applied to determine 
whether the means of the three groups were equal. Since they were not, Scheffe's post-hoc 
comparison was used to determine the pairings that were not equal. In this chart, the 
diabetic group on day 5 had statisticall y significant nodule growth, a=0 .05, when compared 
with the control group on day 5. 
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Photomicrograph Sa. Diabetic Day 0 
: , . . ., . 
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Photomicrograph 6a. Diabetic Day 5 Photomicrograph 6b. Control Day 5 
Photomicrograph 7 a. Diabetic Day S Photomicrograph 7b. Control Day S 
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Photomicrograph Sa. Diabetic Day 12 Photomicrograph Sb. Control Day 12 
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Legend for Photomicrograph Sa and Sb 
Diabetic (Sa) and control (56) mice marrow stromal cell culture nodule formations seen 
under 2x magnification. The photomicrographs show a representative sample. (For 
complete description see 'Protocol for Mineralizing Matix (Nodule) Formation.') 
Legend for Photomicrograph 6a and 6b 
Diabetic (6a) and control (66) mice marrow stromal cell culture nodule formations seen 
under 2x magnification. Mice were injected with P.& 5 days prior to harvesting cells. The 
photomicrographs show a representative sample. (For complete description see 'Protocol 
for Mineralizing Matix (Nodule) Formation.') 
Legend for Photomicrograph 7a and 7b 
Diabetic (7a) and control (76) mice marrow stromal cell culture nodule formations seen 
under 2x magnification. Mice were injected with P.& 8 days prior to harvesting cells. The 
photomicrographs show a representative sample. (For complete description see 'Protocol 
for Mineralizing Matix (Nodule) Formation.') 
Legend for Photomicrograph 8a and 8b 
Diabetic (8a) and control (86) mice marrow stromal cell culture nodule formations seen 
under 2x magnification. Mice were injected with P.& 12 days prior to harvesting cells. The 
photomicrographs show a representative sample. (For complete description see 'Protocol 
for Mineralizing Matix (Nodule) Formation.') 
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Raw Data Processing - Part I - Diabetes Mellitus 
Osteoclast Formation 
Control vs. Diabetic - No Injection (March 26, 2003) 
Summary: Osteoclast Formation for Control and Diabetic - No Injection (March 26, 2003) 
Groups Count Sum Average Variance 
Control (0 ng/ ml) 32 1 0.031 0.031 
Control (111 ng/ ml) 32 207 6.46 34.19 
Control (333 ng/ ml) 32 369 11.53 109.86 
Control (1000 ng/ ml) 32 489 15.28 107.82 
Control (3000 ng/ ml) 32 580 18.12 127.33 
Control (9000 ng/ ml) 32 243 7.59 110.24 
Diabetic (0 ng/ ml) 32 1 0.031 0.031 
Diabetic (111 ng/ ml) 32 258 8.06 27.86 
Diabetic (333 ng/ ml) 32 344 10.75 32.90 
Diabetic (1000 ng/ ml) 32 594 18.56 132.64 
Diabetic (3000 ng/ ml) 32 793 24.78 187.46 
Diabetic (9000 ng/ ml) 32 683 21.34 151.91 
ANOVA Osteoclast Formation for Control and Diabetic - No Injection (March 26, 2003), 
a =0.05 
Source of Variation 
Between Groups 
Within Groups 
Total 
ss 
22260.48 
31692 
53952.48 
df 
11 
317 
MS 
2023 .68 
99.97 
F P-value F crit 
20.24 <0.0001 1.81 
Scheffe's Post-Hoc Comparison: Osteoclast Formation for Control and Diabetic - No 
Injection (March 26, 2003) 
Comparisons Observed Critical ::-::-::• if 
Mean Difference significant 
Difference 
Diabetic 9000 vs. Control 0 21.31 11.15 ,,., .. , 
Diabetic 9000 vs. Diabetic 0 21.31 11.15 :: .. ::•::-
Diabetic 9000 vs. Control 111 14.87 11.15 :: .. ::•::-
Diabetic 9000 vs. Diabetic 111 13.28 11.15 ::-::-::• 
Diabetic 9000 vs. Control 333 9.81 11.15 
Diabetic 9000 vs. Diabetic 333 10.59 11.15 
Diabetic 9000 vs. Control 1000 6.06 11.15 
Diabetic 9000 vs. Diabetic 1000 2.78 11.15 
Diabetic 9000 vs. Control 3000 3.21 11.15 
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Diabetic 9000 vs. Diabetic 3000 -3.43 11.15 
Diabetic 9000 vs. Control 9000 13.75 11.15 ::•::-::• 
Control 9000 vs. Control 0 7.56 11.15 
Control 9000 vs. Diabetic 0 7.56 11.15 
Control 9000 vs. Control 111 1.12 11.15 
Control 9000 vs. Diabetic 111 -0.46 11.15 
Control 9000 vs. Control 333 -3.93 11.15 
Control 9000 vs. Diabetic 333 -3.15 11.15 
Control 9000 vs. Control 1000 -7.68 11.15 
Control 9000 vs. Diabetic 1000 -10.96 11.15 
Control 9000 vs. Control 3000 -10.53 11.15 
Control 9000 vs. Diabetic 3000 -17.18 11.15 ., .. ,,: 
Diabetic 3000 vs. Control 0 24.75 11.15 ::-::-::• 
Diabetic 3000 vs. Diabetic 0 24.75 11.15 ::-::-::-
Diabetic 3000 vs. Control 111 18.31 11.15 ::-::-::-
Diabetic 3000 vs. Diabetic 111 16.71 11.15 ::•::-::• 
Diabetic 3000 vs. Control 333 13.25 11.15 ::-::-::-
Diabetic 3000 vs. Diabetic 333 14.03 11.15 .. , .. , ... 
Diabetic 3000 vs. Control 1000 9.50 11.15 
Diabetic 3000 vs. Diabetic 1000 6.21 11.15 
Diabetic 3000 vs. Control 3000 6.65 11.15 
Control 3000 vs. Control 0 24.75 11.15 ::-::-:: .. 
Control 3000 vs. Diabetic 0 18.09 11.15 ::•::•::-
Control 3000 vs. Control 111 11.65 11.15 ....... 
Control 3000 vs. Diabetic 111 10.06 11.15 
Control 3000 vs. Control 333 6.59 11.15 
Control 3000 vs. Diabetic 333 7.37 11.15 
Control 3000 vs. Control 1000 2.84 11.15 
Control 3000 vs. Diabetic 1000 -0.43 11.15 
Diabetic 1000 vs. Control 0 18.53 11.15 .. , .. , .. ,
Diabetic 1000 vs. Diabetic 0 18.53 11.15 .,.,., 
Diabetic 1000 vs. Control 111 U.09 11.15 ., .. : .. ,
Diabetic 1000 vs. Diabetic 111 10.50 11.15 
Diabetic 1000 vs. Control 333 7.03 11.15 
Diabetic 1000 vs. Diabetic 333 7.81 11.15 
Diabetic 1000 vs. Control 1000 3.28 11.15 
Control 1000 vs. Control 0 15.25 11.15 ::-::-::-
Control 1000 vs. Diabetic 0 15.25 11.15 .... , ... 
Control 1000 vs. Control 111 8.81 11.15 
Control 1000 vs. Diabetic 111 7.21 11.15 
Control 1000 vs. Control 333 3.75 11.15 
Control 1000 vs. Diabetic 333 4.53 11.15 
Diabetic 333 vs . Control 0 10.71 11.15 
Diabetic 333 vs. Diabetic 0 10.71 11.15 
Diabetic 333 vs. Control 111 4.28 11.15 
Diabetic 333 vs. Diabetic 111 2.68 11.15 
Diabetic 333 vs. Control 333 -0.78 11.15 
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Control 333 vs. Control 0 11.50 11.15 ::•::•::-
Control 333 vs. Diabetic 0 11.50 11.15 ,, ...... 
C.Ontrol 333 vs. C.Ontrol 111 5.06 11.15 
C.Ontrol 333 vs. Diabetic 111 3.46 11.15 
Diabetic 111 vs. C.Ontrol 0 8.03 11.15 
Diabetic 111 vs. Diabetic 0 8.03 11.15 
Diabetic 111 vs. C.Ontrol 111 1.59 11.15 
C.Ontrol 111 vs. C.Ontrol 0 6.43 11.15 
C.Ontrol 111 vs. Diabetic 0 6.43 11.15 
Diabetic O vs. C.Ontrol 0 0.00 11.15 
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Control vs. Diabetic - Day 5 Injection (March 26, 2003) 
Summary: Osteoclast Formation for O)Iltrol and Diabetic - Day 5 Injection (March 26, 
2003) 
Groups Count Sum Average Variance 
C.omrol (0 ng/ ml) 32 55 1.71 10.01 
C.ontrol (111 ng/ ml) 32 219 6.84 33.16 
C.ontrol (333 ng/ ml) 32 261 8.15 89.29 
C.ontrol (1000 ng/ ml) 32 400 12.5 122.83 
C.ontrol (3000 ng/ ml) 32 626 19.56 193.80 
C.ontrol (9000 ng/ ml) 32 574 17.93 150.51 
Diabetic (0 ng/ ml) 32 13 0.40 0.63 
Diabetic (111 ng/ ml) 32 323 10.09 68.79 
Diabetic (333 ng/ ml) 32 560 17.5 189.74 
Diabetic (1000 ng/ ml) 32 587 18.34 102.94 
Diabetic (3000 ng/ ml) 24 621 25.87 126.02 
Diabetic (9000 ng/ ml) 32 657 20.53 162.90 
ANOV A: Osteoclast Formation for C.ontrol and Diabetic - Day 5 Injection (March 26, 
2003), a =0.05 
Source of Variation 
Between Groups 
Within Groups 
Total 
ss 
20902.92 
37762.90 
58665.82 
df 
11 
364 
MS 
1900.26 
103.74 
F 
18.31 
P-value F crit 
<D.0001 1.807 
Scheffe's Post-Hoc Comparison: Osteoclast Formation for C.ontrol and Diabetic - Day 5 
Injection (March 26, 2003) 
Comparisons 
Diabetic 9000 vs. Control 0 
Diabetic 9000 vs. Diabetic 0 
Diabetic 9000 vs. Control 111 
Diabetic 9000 vs. Diabetic 111 
Diabetic 9000 vs. C.ontrol 333 
Diabetic 9000 vs. Diabetic 333 
Diabetic 9000 vs . C.ontrol 1000 
Diabetic 9000 vs . Diabetic 1000 
Diabetic 9000 vs. C.ontrol 3000 
Diabetic 9000 vs. Diabetic 3000 
Diabetic 9000 vs . C.ontrol 9000 
Control 9000 vs. Control 0 
Obseived 
Mean 
Difference 
18.81 
20.12 
13.68 
10.43 
9.78 
3.03 
5.43 
2.18 
0.96 
-5.34 
2.59 
16.21 
Critical 
Difference 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
...... if 
significant 
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Control 9000 vs. Diabetic 0 17.53 11.35 ..... , . ,
Control 9000 vs. Control 111 11.09 11.35 
Control 9000 vs. Diabetic 111 7.84 11.35 
Control 9000 vs. Control 333 9.78 11.35 
Control 9000 vs. Diabetic 333 0.43 11.35 
Control 9000 vs. Control 1000 5.43 11.35 
Control 9000 vs. Diabetic 1000 -0.40 11.35 
Control 9000 vs. Control 3000 -1.62 11.35 
Control 9000 vs. Diabetic 3000 -7.93 12.26 
Diabetic 3000 vs. Control 0 24.15 12.26 ::-::◄::◄ 
Diabetic 3000 vs. Diabetic 0 25.46 U.26 ::◄::-:: .. 
Diabetic 3000 vs. Control 111 19.03 U.26 ::-::◄::-
Diabetic 3000 vs. Diabetic 111 15.78 U.26 ::-:: .. ::◄ 
Diabetic 3000 vs. Control 333 17.71 U.26 ::•::-::◄ 
Diabetic 3000 vs. Diabetic 333 8.37 12.26 
Diabetic 3000 vs. Control 1000 13.37 U.26 .. , .. , .... 
Diabetic 3000 vs. Diabetic 1000 7.53 12.26 
Diabetic 3000 vs. Control 3000 6.31 12.26 
Control 3000 vs. Control 0 17.84 11.35 ::-::-::◄ 
Control 3000 vs. Diabetic 0 19.15 11.35 ::◄::-::• 
Control 3000 vs. Control 111 U.71 11.35 .. , ...... , 
Control 3000 vs. Diabetic 111 9.46 11.35 
Control 3000 vs. Control 333 -8.15 11.35 
Control 3000 vs. Diabetic 333 2.06 11.35 
Control 3000 vs. Control 1000 7.06 11.35 
Control 3000 vs. Diabetic 1000 -372.43 11.35 :: .. ::-::◄ 
Diabetic 1000 vs. Control 0 16.62 11.35 ::-::-::• 
Diabetic 1000 vs. Diabetic 0 17.93 11.35 ::•::◄ ::-
Diabetic 1000 vs. Control 111 11.50 11.35 ::-::◄::--
Diabetic 1000 vs. Diabetic 111 8.25 11.35 
Diabetic 1000 vs. Control 333 10.18 11.35 
Diabetic 1000 vs. Diabetic 333 0.84 11.35 
Diabetic 1000 vs. Control 1000 5.84 11.35 
Control 1000 vs. Control 0 10.78 11.35 
Control 1000 vs. Diabetic 0 U.09 11.35 ::-::◄::-
Control 1000 vs. Control 111 5.65 11.35 
Control 1000 vs. Diabetic 111 2.40 11.35 
Control 1000 vs. Control 3 3 3 4.34 11.35 
Control 1000 vs. Diabetic 333 -5.00 11.35 
Diabetic 333 vs. Control 0 15.78 11.35 ::◄::-::-
Diabetic 333 vs. Diabetic 0 17.09 11.35 ::-::-::-
Diabetic 333 vs. Control 111 384.15 11.35 ::-::•::-
Diabetic 333 vs. Diabetic 111 7.40 11.35 
Diabetic 333 vs. Control 333 9.34 11.35 
Control 3 3 3 vs. Control 0 6.43 11.35 
Control 333 vs. Diabetic 0 7.75 11.35 
Control 333 vs. Control 111 378.15 11.35 ., .. , .. ,
66 
Control 333 vs. Diabetic 111 
Diabetic 111 vs. Control 0 
Diabetic 111 vs. Diabetic 0 
Diabetic 111 vs. Control 111 
Control 111 vs. Control 0 
Control 111 vs. Diabetic 0 
Diabetic O vs. Control 0 
-1.93 
8.37 
9.68 
3.25 
5.12 
6.43 
-1.31 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
11.35 
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Control vs. Diabetic - Day 8 Injection (April 29, 2003) 
Summary: Osteoclast Formation for O:mtrol and Diabetic - Da y 8 Injection (April 29, 
2003) 
Groups Count Sum Average Variance 
Control (0 ng/ ml) 32 22 0.68 1.25 
Control (111 ng/ ml) 32 52 1.62 1.27 
Control (333 ng/ ml) 32 30 0.93 0.77 
Control (1000 ng/ ml) 32 77 2.40 4.63 
Control (3000 ng/ ml) 32 69 2.15 1.29 
Control (9000 ng/ ml) 32 89 2.78 4.62 
Dia be tic ( 0 ng/ ml) 32 66 2.06 6.31 
Diabetic (111 ng/ ml) 32 82 2.56 5.47 
Diabetic (333 ng/ ml) 32 89 2.78 6.04 
Diabetic (1000 ng/ ml) 32 66 2.06 3.15 
Di a be tic ( 3 000 ng/ ml) 32 74 2.31 3.38 
Diabetic (9000 ng/ ml) 32 101 3.15 2.91 
ANOV A; Osteoclast Formation for Control and Diabetic - Da y 8 Injection (April 29, 
2003), ex =0.05 
Source of Variation 
Between Groups 
Within Groups 
Total 
ss 
190.90 
1275.84 
1466.74 
df 
11 
372 
MS 
17.35 
3.42 
F P-value F crit 
5.06 <0.0001 1.80 
Scheffe's Post-Hoc Comparison: Osteoclast Formation for Control and Diabetic - Day 8 
Injection (A ril 29, 2003) 
Comparisons Observed Critical ::-::-::• if 
Diabetic 9000 vs. Control 0 
Diabetic 9000 vs. Diabetic 0 
Diabetic 9000 vs. Control 111 
Diabetic 9000 vs. Diabetic 111 
Diabetic 9000 vs. Control 333 
Diabetic 9000 vs. Diabetic 333 
Diabetic 9000 vs. Control 1000 
Diabetic 9000 vs. Diabetic 1000 
Diabetic 9000 vs. Control 3000 
Diabetic 9000 vs. Diabetic 3000 
Diabetic 9000 vs. Control 9000 
Control 9000 vs. Control 0 
Mean 
Difference 
2.46 
1.09 
1.53 
0.59 
2.21 
0.37 
0.75 
1.09 
1.00 
0.84 
0.37 
2.09 
Difference 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
significant 
........... , 
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Control 9000 vs. Diabetic 0 0.71 2.06 
Control 9000 vs. Control 111 1.15 2.06 
Control 9000 vs. Diabetic 111 0.21 2.06 
Control 9000 vs. Control 3 3 3 1.84 2.06 
Control 9000 vs. Diabetic 333 0.00 2.06 
Control 9000 vs. Control 1000 0.375 2.06 
Control 9000 vs. Diabetic 1000 0.71 2.06 
Control 9000 vs. Control 3000 0.62 2.06 
Control 9000 vs. Diabetic 3000 0.46 2.06 
Diabetic 3000 vs. Control 0 1.62 2.06 
Diabetic 3000 vs. Diabetic 0 0.25 2.06 
Diabetic 3000 vs. Control 111 0.68 2.06 
Diabetic 3000 vs. Diabetic 111 -0.25 2.06 
Diabetic 3000 vs. Control 333 1.37 2.06 
Diabetic 3000 vs. Diab etic 333 -0.46 2.06 
Diabetic 3000 vs. Control 1000 -0.09 2.06 
Diabetic 3000 vs. Diabetic 1000 0.25 2.06 
Diabetic 3000 vs. Control 3000 0.15 2.06 
Control 3000 vs. Control 0 1.46 2.06 
Coritrol 3000 vs. Diabetic 0 0.09 2.06 
Control 3000 vs. Control 111 0.53 2.06 
Control 3000 vs. Diabetic 111 -0.40 2.06 
Control 3000 vs. Control 333 1.21 2.06 
Control 3000 vs. Diabetic 333 -0.62 2.06 
Control 3000 vs. Control 1000 -0.25 2.06 
Control 3000 vs. Diabetic 1000 0.093 2.06 
Diabetic 1000 vs. Control 0 1.37 2.06 
Diabetic 1000 vs. Diabetic 0 0.00 2.06 
Diabetic 1000 vs. Control 111 0.43 2.06 
Diabetic 1000 vs. Diabetic 111 -0.50 2.06 
Diabetic 1000 vs. Control 333 1.12 2.06 
Diabetic 1000 vs. Diabetic 333 -0.71 2.06 
Diabetic 1000 vs. Control 1000 -0.34 2.06 
Control 1000 vs. Control 0 1.71 2.06 
Control 1000 vs. Diabetic 0 0.34 2.06 
Control 1000 vs. Control 111 0.78 2.06 
Control 1000 vs. Diabetic 111 -0.15 2.06 
Control 1000 vs. Control 333 1.46 2.06 
Control 1000 vs. Diabetic 333 -0.37 2.06 
Diabetic 333 vs . Control 0 2.09 2.06 ::•::•::-
Diabetic 333 vs. Diabetic 0 0.71 2.06 
Diabetic 333 vs. Control 111 1.15 2.06 
Diabetic 333 vs. Diabetic 111 0.21 2.06 
Diabetic 333 vs. Control 333 1.84 2.06 
Control 3 3 3 vs. Control 0 0.25 2.06 
Control 333 vs. Diabetic 0 -1.12 2.06 
Control 333 vs. Control 111 -0.68 2.06 
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O:mtrol 333 vs. Diabetic 111 
Diabetic 111 vs. Control 0 
Diabetic 111 vs. Diabetic 0 
Diabetic 111 vs. Control 111 
Control 111 vs. Control 0 
Control 111 vs. Diabetic 0 
Diabetic O vs. Control 0 
-1.62 
1.87 
0.50 
0.93 
0.93 
-0.43 
1.37 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
2.06 
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Control vs . Diabet ic - Day 12 Injection (Mar ch 26, 2003) 
Summary: Osteoclast Formation for Control and Diabetic - Day 12 Injection (March 26, 
2003) 
Groups Count Sum Average Variance 
Control (0 ng/ ml) 32 47 1.46 2.90 
Control ( 111 ng/ ml) 32 155 4.84 9.61 
Control (333 ng/ ml) 32 245 7.65 25.20 
Control (1000 ng/ ml) 0 
Control (3000 ng/ ml) 8 54 6.75 13.64 
Control (9000 ng/ ml) 32 163 5.09 18.47 
Diabetic (0 ng/ ml) 32 17 0.53 5.28 
Diabetic (111 ng/ ml) 32 80 2.50 7.87 
Diabetic (333 ng/ ml) 32 151 4.71 31.43 
Diabetic (1000 ng/ ml) 32 233 7.28 50.40 
Diabetic (3000 ng/ ml) 32 145 4.53 18.83 
Diabetic (9000 ng/ ml) 32 156 4.87 33.01 
AN OV A: Osteoclast Formation for Control and Diabetic - Day 12 Injection (March 26, 
2003), a =0.05 
Source of Variation ss df MS F P-value F crit 
Between Groups 
Within Groups 
Total 
1551.25 
6390 
7941.25 
10 
317 
155.12 
20.15 
7.69 <0.0001 1.89 
Scheffe's Post -Hoc Comparison : Osteoclast Formation for Control and Diabetic - Day 
12 Injection (March 26, 2003) 
Comparisons Observed Critical ::-::-::-if 
Mean Difference significant 
D ifference 
Diabetic 9000 vs. Control 0 3.40 4.88 
Diabetic 9000 vs. Diabetic 0 4.34 4.88 
Diabetic 9000 vs. Control 111 0.03 4.88 
Diabetic 9000 vs. Diabetic 111 2.375 4.88 
Diabetic 9000 vs. Control 3 3 3 -2.78 4.88 
Diabetic 9000 vs. Diabetic 333 0.15 4.88 
Diabetic 9000 vs. Control 1000 
Diabetic 9000 vs. Diabetic 1000 -2.40 4.88 
Diabetic 9000 vs. Control 3000 -1.87 7.71 
Diabetic 9000 vs. Diabetic 3000 0.34 4.88 
Diabetic 9000 vs. Control 9000 -0 .21 4.88 
Control 9000 vs. Control 0 3.62 4.88 
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Gmtrol 9000 vs. Diabetic 0 4.56 4.88 
Control 9000 vs. Contro l 111 0.25 4.88 
Contro l 9000 vs. Diabetic 111 2.59 4.88 
Control 9000 vs. Contro l 333 -2.78 4.88 
Control 9000 vs. D iabetic 333 0.15 4.88 
Contro l 9000 vs. Control 1000 
Control 9000 vs. D iabetic 1000 -2.18 4.88 
Contro l 9000 vs. Control 3000 -1.65 7.71 
Control 9000 vs. Diabetic 3000 0.56 4.88 
Diabetic 3000 vs. Control 0 3.06 4.88 
Diabetic 3000 vs. Diabetic 0 4.00 4.88 
Diabetic 3000 vs. Control 111 -0.31 4.88 
Diabetic 3000 vs. Diabetic 111 2.03 4.88 
Diabetic 3000 vs. Control 333 -3.12 4.88 
D iabetic 3000 vs. Diabetic 333 -0.18 4.88 
Diabetic 3000 vs. Control 1000 
Diabetic 3000 vs. Diabetic 1000 -2.75 4.88 
Diabetic 3000 vs. Control 3000 -2.21 7.71 
Control 3000 vs. Control 0 5.28 7.71 
Control 3000 vs. Diabetic 0 6.21 7.71 
Control 3000 vs. Control 111 1.90 7.71 
Control 3000 vs. Diabetic 111 4.25 7.7 1 
Control 3000 vs. Control 333 -0.90 7.71 
Contro l 3000 vs. Diabetic 333 2.03 7.71 
Control 3000 vs. Contro l 1000 
Control 3000 vs. Diabetic 1000 -0.53 7.71 
Diabetic 1000 vs. Control 0 5.81 4.88 ~:-:• ::• 
Diabetic 1000 vs. Diabetic 0 6.75 4.88 .. ...... , 
D iabetic 1000 vs. Control 111 2.43 4.88 
Diabetic 1000 vs. Diabetic 111 4.78 4.88 
Diabetic 1000 vs. Control 333 -0.37 4.88 
Diabetic 1000 vs. Diabetic 333 2.56 4.88 
Diabet ic 1000 vs. Control 1000 
Control 1000 vs. Contro l 0 
Control 1000 vs. Diabetic 0 
Control 1000 vs. Contro l 111 
Control 1000 vs. Diabetic 111 
Control 1000 vs. Contro l 333 
Control 1000 vs. Diabetic 333 
Diabetic 333 vs. Contro l 0 3.25 4.88 
Diabetic 333 vs. Diabetic 0 4.18 4.88 
Diabetic 333 vs. Control 111 -0.12 4.88 
Diabetic 333 vs. Diabetic 111 2.21 4.88 
Diabetic 333 vs. Contro l 333 -2.93 4.88 
Control 333 vs. Control 0 6.18 4.88 , ,,, .... 
Control 333 vs. Di abetic 0 7.12 4.88 ::-::- :-
Control 333 vs. Control 111 2.81 4.88 
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Control 333 vs. Diabetic 111 
Diabetic 111 vs. Control 0 
Diabetic 111 vs. Diabetic 0 
Diabetic 111 vs. Control 111 
Control 111 vs. Control 0 
Control 111 vs. Diabetic 0 
Diabetic O vs. Control 0 
5.15 
1.03 
1.96 
-2.34 
3.37 
4.31 
-0.93 
4.88 
4.88 
4.88 
4.88 
4.88 
4.88 
4.88 
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Control vs. Diabetic - Time Course (March 26, 2003 and April 29, 2003) 
Summary: Osteoclast Formation for Control and Diabetic - Time Course (March 26, 2003 
and April 29, 2003) 
Groups Count Sum Average Variance 
Control (0 ng/ ml-0 Day) 32 1 0.03 0.03 
Control (0 ng/ ml-5 Da~ 32 55 1.71 10.01 
Control (0 ng/ ml-8 D ay) 32 22 0.68 1.25 
Control (0 ng/ ml-12 D ay) 32 47 1.46 2.90 
Diabetic (0 ng/ ml-0 Da~ 32 1 0.03 0.03 
Diabetic (0 ng/ ml-5 Da~ 32 13 0.40 0.63 
Diab etic (0 ng/ ml-8 Da~ 32 66 2.06 6.31 
Diabeti c (0 ng/ ml-12 D a~ 32 17 0.53 5.28 
Control (9000 ng/ ml-0 Da~ 32 243 7.59 110.24 
Control (9000 ng/ ml-5 Da~ 32 574 17.93 150.51 
Control (9000 ng/ ml-8 Day) 32 89 2.78 4.62 
Control (9000 ng/ ml-12 Day) 32 163 5.09 18.47 
Diabetic (9000 ng/ ml-0 Day) 32 683 21.34 151.91 
Diabetic (9000 ng/ ml-5 Day) 32 657 20.53 162.90 
Diabetic (9000 ng/ ml-8 Da~ 32 101 3.15 2.91 
Di abetic (9000 ng/ ml-12 Da~ 32 156 4.87 33.01 · 
AN OV A: Osteoclast Formation for Control and D iabetic - Time Course (March 26, 2003 
and April 29, 2003), a =0.05 
Source of Variation 
Between Groups 
Within Groups 
Tota l 
ss 
26404.37 
20493.5 
46897.87 
df 
15 
498 
MS 
1760.29 
41.15 
F P-value F crit 
42.77 <0.0001 1.71 
Scheffe's Post -Hoc Comparison: Osteoclast Formation for Control and Diabetic - Time 
Course (March 26, 2003 and April 29, 2003) 
Comparis ons Obseived Mean Critical ::-::-::-if 
Difference Difference significant 
Control (0 ng/ ml-0 Day) - -1.68 8.13 
Control (Ong/ ml-5 Da~ 
Control (0 ng/ ml-0 Day) - -0.65 8.13 
Control (Ong/ ml-8 Da~ 
Control (0 ng/ ml-0 Day) - -1.43 8.13 
Control (Ong/ ml-12 Day) 
Control (0 ng/ ml-0 Da~ - -7.56 8.13 
Contro l (9000ng/ ml-0 Da~ 
74 
Control ( 0 ng/ ml-0 Day) - -17.90 8.13 ::•::-::• 
Control (9000ng/ ml-5 Day) 
C.Ontrol (0 ng/ ml-0 Da~ - -2.75 8.13 
C.Ontrol (9000ng/ ml-8 Day) 
C.Ontrol (0 ng/ ml-0 Day) - -5.06 8.13 
C.Ontrol (9000ng/ ml-12 Da~ 
C.Ontrol (0 ng/ ml-0 Da~ - 0 8.13 
Diabetic (Ong/ ml-0 Day) 
C.Ontrol (0 ng/ ml-0 Da~ - -0.37 8.13 
Diabetic (Ong/ ml-5 Da~ 
C.Ontrol (0 ng/ ml-0 Day) - -2.03 8.13 
Diabetic (Ong/ ml-8 Da~ 
C.Ontrol (0 ng/ ml-0 Day) - -0.50 8.13 
Diabetic (Ong/ ml-12 Day) 
Control (0 ng/ml-0 Day) - -21.31 8.13 ::•::-::-
Diabetic ( 9000ng/ ml-0 Day) 
Control (0 ng/ ml-0 Day) - -20.50 8.13 .. , ..... , 
Diabetic (9000ng/ ml-5 Day) 
C.Ontrol (0 ng/ ml-0 Day) - -3.12 8.13 
Diabetic (9000ng/ ml-8 Da~ 
C.Ontrol (0 ng/ ml-0 Day) - -4.84 8.13 
Diabetic (9000ng/ ml-12 Day) 
C.Ontrol (0 ng/ ml-5 Day) - 1.03 8.13 
C.Ontrol (Ong/ ml-8 Da~ 
C.Ontrol (0 ng/ ml-5 Da~ - 0.25 8.13 
C.Ontrol (Ong/ ml-12 Day) 
C.Ontrol (0 ng/ ml-5 Day) - -5.87 8.13 
C.Ontrol (9000ng/ ml-0 Day) 
Control (0 ng/ml-5 Day) - -16.21 8.13 .,, ....... 
Control (9000ng/ml-5 Day) 
C.Ontrol (0 ng/ ml-5 Day) - -1.06 8.13 
C.Ontrol (9000ng/ ml-8 Da~ 
C.Ontrol (0 ng/ ml-5 Day) - -3.37 8.13 
C.Ontrol (9000ng/ ml-12 Day) 
C.Ontrol (0 ng/ ml-5 Day) - 1.68 8.13 
Diabetic (Ong/ ml-0 Da~ 
C.Ontrol (0 ng/ ml-5 Day) - 1.31 8.13 
Diabetic (Ong/ ml-5 Day) 
C.Ontrol (0 ng/ ml-5 Da~ - 1.03 8.13 
Diabetic (Ong/ ml-8 Day) 
C.Ontrol (0 ng/ ml-5 Day) - 1.18 8.13 
Diabetic (Ong/ ml-12 Da~ 
Control ( 0 ng/ ml-5 Day) - -19.62 8.13 .. ,., ... 
Diabetic (9000ng/ml-0 Day) 
Control (0 ng/ml-5 Day) - -18.81 8.13 ::-::• :• 
Diabetic (9000ng/ ml-5 Day) 
C.Ontrol (0 ng/ ml-5 Day) - -1.43 8.13 
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Diabetic (9000ng/ ml-8 Day) 
Control (0 ng/ ml-5 Day) - -3.15 8.13 
Diabetic (9000ng/ ml-12 Day) 
Control (0 ng/ ml-8 Da y) - -0.78 8.13 
Control (Ong/ ml-12 Da)0 
Control (0 ng/ ml-8 Da)0 - -6.90 8.13 
Control (9000ng/ ml-0 Da y) 
Control (0 ng/ml-8 Day) - -17.25 8.13 ........ 
Control (9000ng/ml-5 Day) 
Control (0 ng/ ml-8 Da)0 - -2.09 8.13 
Control (9000ng/ ml-8 Day) 
Control (0 ng/ ml-8 Da)0 - -4.40 8.13 
Control (9000ng/ ml-12 Da )0 
Control (0 ng/ ml-8 Day) - 0.65 8.13 
Diabetic (Ong/ ml-0 Da y) 
Control (0 ng/ ml-8 Da)0 - 0.28 8.13 
Diabetic (Ong/ ml-5 Da)0 
Control (0 ng/ ml-8 Day) - -1.37 8.13 
Diabetic (Ong/ ml-8 Day) 
Control (0 ng/ ml-8 Da y) - 0.15 8.13 
Diabetic (Ong/ ml-12 Da y) 
Control ( 0 ng/ ml-8 Day) - -20.65 8.13 ,, .. , ... 
Diabetic ( 9000ng/ ml-0 Day) 
Control (0 ng/ml-8 Day) - -19.84 8.13 .,,, ... ,
Diabetic (9000ng/ml-5 Day) 
Control (0 ng/ ml-8 Day) - -2.46 8.13 
Diabetic (9000ng/ ml-8 Day) 
Control (0 ng/ ml-8 Da y) - -4.18 8.13 
Diabetic (9000ng/ ml-12 Da)0 
Control (0 ng/ ml-12 D ay) - -6.12 8.13 
Control (9000ng/ ml-0 Da y) 
Control (0 ng/ ml- U Day) - -16.46 8.13 ,,,,., 
Control (9000ng/ ml-5 Day) 
Control (0 ng/ ml-12 Da y) - -1.31 8.13 
Control (9000ng/ ml-8 Day) 
Control (0 ng/ ml-12 Da)0 - -3.62 8.13 
Control (9000ng/ ml-12 Da)0 
Control (0 ng/ ml-12 Day) - 1.43 8.13 
Diabetic (Ong/ ml-0 Day) 
Control (0 ng/ ml-12 Da)0 - 1.06 8.13 
Diabetic (Ong/ ml-5 Day) 
Control (0 ng/ ml-12 Da)0 - -0.59 8.13 
Diabetic (Ong/ ml-8 Da)0 
Control (0 ng/ ml-12 Day) - 0.93 8.13 
Diabetic (Ong/ ml-12 Day) 
Control (0 ng/ ml-12 Day) - -6.12 8.13 
Diabetic (9000ng/ ml-0 Da)0 
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Control ( 0 ng/ ml-12 Day) - -19.06 8.13 "'''''' 
Diabetic (9000ng/ ml-5 Day) 
Control (0 ng/ml-12 Day) - -1.68 8.13 
Diabetic (9000ng/ ml-8 Da y) 
Control (0 ng/ ml-12 Da y) - -3.40 8.13 
Diabetic (9000ng/ ml-12 Day) 
Control (9000 ng/ml-0 Day) -10.34 8.13 ::-::•::-
- Control (9000ng/ ml-5 
Day) 
Control (9000 ng/ ml-0 Da y) - 4.81 8.13 
Control (9000ng/ ml-8 Da y) 
Control (9000 ng/ ml-0 Da:0 - 2.50 8.13 
Control (9000ng/ ml-12 Da:0 
Control (9000 ng/ ml-0 Da:0 - 7.56 8.13 
Diabetic (Ong/ ml-0 Da y) 
Control (9000 ng/ ml-0 Da y) - 7.18 8.13 
Diabetic (Ong/ ml-5 Da:0 
Control (9000 ng/ ml-0 Da y) - 5.53 8.13 
Diabetic (Ong/ ml-8 Da:0 
Control (9000 ng/ ml-0 Da:0 - 7.06 8.13 
Diabetic (Ong/ ml-12 Da:0 
Control (9000 ng/ml-0 Day) -13.75 8.13 .......... 
- Diabetic ( 9000ng/ ml-0 
Day) 
Control (9000 ng/ml-0 Day) -12.93 8.13 ::•::-::• 
- Diabetic (9000ng/ ml-5 
Day) 
Control (9000 ng/ ml-0 Da:0 - 4.43 8.13 
Diabetic (9000ng/ ml-8 Da:0 
Control (9000 ng/ ml-0 Da y) - 2.71 8.13 
Diabetic (9000ng/ ml-12 Da:0 
Control (9000 ng/ ml-5 Day) 15.15 8.13 :: .. ::-::-
- Control ( 9000ng/ ml- 8 
Day) 
Control (9000 ng/ ml-5 Day) 12.84 8.13 ::-::-::-
- Control ( 9000ng/ ml-12 
Day) 
Control (9000 ng/ml-5 Day) 17.90 8.13 ::-::-::-
-Diabetic (Ong/ml-0 Day) 
Control (9000 ng/ ml-5 Day) 17.53 8.13 :: .. ::-::-
-Diabetic (Ong/ml-5 Day) 
Control (9000 ng/ml-5 Day) 15.87 8.13 ::-::-::-
-Diabetic (Ong/ ml-8 Day) 
Control (9000 ng/ ml-5 Day) 17.40 8.13 :: .. :: .. ::• 
-Diabetic (Ong/ml-12 Day) 
Control (9000 ng/ ml-5 Da:0 - -3.40 8.13 
Diabetic (9000ng/ ml-0 Day) 
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C.Ontrol (9000 ng/ ml-5 Day) - -2.59 8.13 
Diabetic (9000ng/ ml-5 Day) 
Control (9000 ng/ ml-5 Day) 14.78 8.13 :: .. ::•::• 
-Diabetic (9000ng/ ml-8 
Da y) 
Control ( 9000 ng/ ml-5 Day) 13.06 8.13 ::-::•::-
-Diabetic (9000ng/ ml- U 
Da y) 
C.Ontrol (9000 ng/ ml-8 Day) - -2.31 8.13 
C.Ontrol (9000ng/ ml-12 Day) 
C.Ontrol (9000 ng/ ml-8 DayJ - 2.75 8.13 
Diabetic (Ong/ ml-0 DayJ 
C.Ontrol (9000 ng/ ml-8 DayJ - 2.37 8.13 
Diabetic (Ong/ ml-5 Day) 
C.Ontrol (9000 ng/ ml-8 Day) - 0.71 8.13 
Diabetic (Ong/ ml-8 Day) 
C.Ontrol (9000 ng/ ml-8 Day) - 2.25 8.13 
Diabetic (Ong/ ml-12 DayJ 
Control (9000 ng/ ml-8 Day) -18.56 8.13 ,, .. , .. ,
-Diabetic (9000ng/ ml-0 
Day) 
Control ( 9000 ng/ ml-8 Da y) -17.75 8.13 ,,,,,., 
-Diabetic ( 9000ng/ ml-5 
Day) 
C.Ontrol (9000 ng/ ml-8 Day) - -0.37 8.13 
Diabetic (9000ng/ ml-8 DayJ 
C.Ontrol (9000 ng/ ml-8 DayJ - -2.31 8.13 
Diabetic (9000ng/ ml-12 Day) 
C.Ontrol (9000 ng/ ml-12 Day) - 5.06 8.13 
Diabetic (Ong/ ml-0 Day) 
C.Ontrol (9000 ng/ ml-12 Day) - 4.68 8.13 
Diabetic (Ong/ ml-5 Day) 
C.Ontrol (9000 ng/ ml-12 Day) - 3.03 8.13 
Diabetic (Ong/ ml-8 DayJ 
C.Ontrol (9000 ng/ ml-12 Day) - 4.56 8.13 
Diabetic (Ong/ ml-12 DayJ 
Control (9000 ng/ml-U Da y) -16.25 8.13 .. , .. , ... 
-Diabetic ( 9000ng/ ml-0 
Day) 
Control ( 9000 ng/ ml- U Day) -15.43 8.13 :: .. ::-::• 
-Diabetic (9000ng/ ml-5 
Day) 
C.Ontrol (9000 ng/ ml-12 Day) - 1.93 8.13 
Diabetic (9000ng/ ml-8 Day) 
C.Ontrol (9000 ng/ ml-12 Day) - 0.21 8.13 
Diabetic (9000ng/ ml-12 DayJ 
Diabetic (0 ng/ ml-0 Day) - -0.37 8.13 
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Diabetic (Ong/ ml-5 DaYJ 
Diabetic (0 ng/ ml-0 Day) - -2.03 8.13 
Diabetic (Ong/ ml-8 Day) 
Diabetic (0 ng/ ml-0 Day) - -0.50 8.13 
Diabetic (Ong/ ml-12 Day) 
Diabetic (0 ng/ml-0 Day) - -21.31 8.13 ::-::-::-
Diabetic (9000ng/ ml-0 Day) 
Diabetic (0 ng/ml-0 Day) - -20.50 8.13 .. , .. , .. ,
Diabetic (9000ng/ ml-5 Day) 
Diabetic (0 ng/ ml-0 DaYJ - -3.12 8.13 
Diabetic (9000ng/ ml-8 DaYJ 
Diabetic (0 ng/ ml-0 DaYJ - -4.84 8.13 
Diabetic (9000ng/ ml-12 Day) 
Diabetic (0 ng/ ml-5 Day) - -1.65 8.13 
Diabetic (Ong/ ml-8 Day) 
Diabetic (0 ng/ ml-5 DaYJ - -0.12 8.13 
Diabetic (Ong/ ml-12 Day) 
Diabetic (0 ng/ml-5 Day) - -20.93 8.13 ::•::-::-
Diabetic (9000ng/ml-0 Day) 
Diabetic (0 ng/ml-5 Day) - -20.U 8.13 ,, .. , .. ,
Diabetic (9000ng/ ml-5 Day) 
Diabetic (0 ng/ ml-5 DaYJ - -2.75 8.13 
Diabetic (9000ng/ ml-8 DaYJ 
Diabetic (0 ng/ ml-5 DaYJ - -4.46 8.13 
Diabetic (9000ng/ ml-12 DaY) 
Diabetic (0 ng/ ml-8 DaYJ - 1.53 8.13 
Diabetic (Ong/ ml-12 Day) 
Diabetic (0 ng/ml-8 Day) - -19.28 8.13 ::-::-::• 
Diabetic (9000ng/ ml-0 Day) 
Diabetic (0 ng/ ml-8 Day) - -18.46 8.13 ::-:: .. :-
Diabetic (9000ng/ ml-5 Day) 
Diabetic (0 ng/ ml-8 Day) - -1.09 8.13 
Diabetic (9000ng/ ml-8 Day) 
Diabetic (0 ng/ ml-8 Day) - -2.81 8.13 
Diabetic (9000ng/ ml-12 Day) 
Diabetic (0 ng/ml-U Day) - -20.81 8.13 ::-::•::-
Diabetic (9000ng/ml-0 Day) 
Diabetic ( 0 ng/ ml- U Day) - -20.00 8.13 .. , ..... , 
Diabetic (9000ng/ ml-5 Day) 
Diabetic (0 ng/ ml-12 Day) - -2.62 8.13 
Diabetic (9000ng/ ml-8 Day) 
Diabetic (0 ng/ ml-12 Day) - -4.34 8.13 
Diabetic (9000ng/ ml-12 DaYJ 
Diabetic (9000 ng/ ml-0 Day) - 0.81 8.13 
Diabetic (9000ng/ ml-5 Day) 
Diabetic (9000 ng/ ml-0 Day) 18.18 8.13 .. , .. , .. ,
-Diabetic ( 9000n I ml-8 
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Day) 
Diabetic (9000 ng/ml-0 Day) 16.46 8.13 ......... 
-Diabetic (9000ng/ ml- U 
Day) 
Diabetic (9000 ng/ ml-5 Day) 17.37 8.13 ~:-::-::• 
-Diabetic ( 9000ng/ ml-8 
Day) 
Diabetic (9000 ng/ ml-5 Day) 15.65 8.13 .. , ... , ... 
-Diabetic (9000ng/ ml-12 
Day) 
Diabetic (9000 ng/ ml-8 Da)1 - -1.71 8.13 
Diabetic (9000ng/ ml-12 Day) 
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Nodule Formation 
Control vs. Diabetic 
Summary: Combined Nodule Formation for Control and Diabetic Oanuary 27, February 4, 
April 29, 2003) 
Groups Count Sum Average Variance 
Control- No Injection 29 147.73 5.09 44.61 
Diabetic - No Injection 30 137.05 4.56 25.56 
Control - Day 5 Injection 12 114.12 9.51 63.11 
Diabetic - Day 5 12 227.96 18.99 21.16 
Injection 
Control - Day 8 12 190.04 15.83 72.42 
Injection 
Diabetic - Day 8 12 293.13 24.42 60.80 
Injection 
ANOVA: Combined Nodule Formation for Control and Diabetic Oanuary 27, February 4, 
April 29, 2003), a=0.05 
Source of Variation 
Between Groups 
Within Groups 
Total 
ss 
5449.10 
4383.19 
9832.30 
df 
5 
103 
MS 
1089.82 
42.55 
F P-value F crit 
25.60 <0.0001 2.30 
Scheffe's Post-Hoc Comparison: Combined Nodule Formation for Control and Diabetic 
Qanuary 27, February 4, April 29, 2003) 
Comparisons Observed Critical *** if 
Diabetic 8 vs. Control 0 
Diabetic 8 vs. Diabetic 0 
Diabetic 8 vs. Control 5 
Diabetic 8 vs. Diabetic 5 
Diabetic 8 vs. Control 8 
Control 8 vs. Control 0 
Control 8 vs. Diabetic 0 
Control 8 vs. Control 5 
Control 8 vs. Diabetic 5 
Diabetic 5 vs. Control 0 
Diabetic 5 vs. Diabetic 0 
Diabetic 5 vs. Control 5 
Control 5 vs. Control 0 
Control 5 vs. Diabetic 0 
Diabetic 0 vs. Control 0 
Mean 
Difference 
19.33 
19.85 
14.91 
5.43 
8.59 
10.74 
11.26 
6.32 
-3.15 
19.33 
14.42 
9.48 
4.41 
4.94 
-0.52 
Difference 
7.59 
7.56 
9.03 
9.03 
9.03 
7.59 
7.56 
9.03 
9.03 
7.59 
7.56 
9.03 
7.59 
7.56 
5.76 
significant 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
*** 
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Discussion - Part I - Diabetes Mellitus 
Bacteria, which are known to cause bone resorption, make their presence evident through a 
variety of bone diseases. Specific examples of this include lesions of endodontic or 
periodontal origin. These infections caused by bacteria become more complex when 
combined with an endocrine disease such as diabetes mellitus. The effect of diabetes on 
bone is significant in two major ways. Not only does diabetes affect the functional integrity 
of the bone itself, it causes a noticeable change in the bone marrow stromal cell lineage 
immune response, thus having deleterious effects throughout the body. Despite our 
scientific advances, little is known regarding the effects of diabetes mellitus on endodontic 
infections. 275 Previous studies have shown that there is a pathway, independent of 
osteoblasts, allowing the development of osteoclast like, TRAP positive, multinucleated 
cells.148 Based on this phenomenon, these experiments continued with this line of reasoning 
to compare the diabetic type II model using bone marrow cells with respect to both 
osteoclast and nodule formation. 
Osteoclast formation experiments over a 12 day time course yielded interesting results. The 
osteoclast experiments indicate that, without LPS stimulation, osteoclast development is 
minimal or nonexistent in both the diabetic and control cultures over all time points. With 
LPS stimulation on day 0, without in vivo bacterial injection, the diabetic marrow cell culture 
produces high numbers of osteoclasts compared with the control culture. Although the 
osteoclast numbers in the control culture are not as high as the diabetic culture, without in 
vivo bacterial injection, the numbers of osteoclasts are equivalent using marrow cells 5 days 
after the bacterial injection. The control response appears to require time to match the 
response seen by the diabetic model. This is possibly due to the diabetic marrow cells being 
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'primed' to pre-existing inflammatory stimulation, and thus after further bacterial 
stimulation, lead to accelerated osteoclast formation, which might lead to rapid bone loss. 
Once the control matches the response of the diabetic model, the two models appear to be 
operate in a parallel fashion. 
The explanation of the 'priming' of the marrow cells has been offered by Grossi and 
Genco. 276 When mononuclear phagocytes interact with advanced glycation end product 
(AGE) modified proteins, whose formation is hyperglycemia mediated, it results in the 
upregulation of cytokine expression and induction of oxidative stress.277 AGEs have been 
described as chemically irreversible, glucose-derived compounds that form slowly and 
continuosly as a result of blood glucose concentration. 278 Besides being found in diabetic 
plasma and tissues306 they have also been found in the gingiva of diabetic individuals.305 
Important cells that have high-affinity receptors for a common structural element on AGE-
modified proteins are macrophages. 279 It is the binding of the AGE-modified protein to the 
macrophage receptor (RAGE) which initiates a cycle of cytokine upregulation, with synthesis 
of primarily IL-1 and TNF-a which may then bind to cells involved in normal tissue 
remodeling. They argue that it would then follow that monocytes in individuals with 
diabetes may be 'primed' by AGE-protein binding. It follows that an infection which 
challenges these cells may amplify the magnitude of the macrophage response to AGE-
protein, thereby enhancing cytokine production and oxidative stress. 
The nodule experiments conducted over an 8 day time course resulted in the following 
observations. Nodule growth in both diabetic and control models was identical at day 0, 
where no bacterial stimulation was applied. However by day 5, with bacterial stimulation, 
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the nodule formation in the diabetic group was significantly higher than in the control group. 
The diabetic culture nodule formation continues to rise with the 8th day bacterial stimulation, 
although it lacks the growth intensity noted between day O and 5. The control cultures, on 
the other hand, increased between the three time points, but at no time did they match the 
levels reached by the diabetic culture. Overall, the nodule formation in the diabetic model 
appears much stronger than the control model and appears to stay at that elevated level, 
whereas the control group appears to result in slower nodule formation. 
Previous experiments have found that significant differences are noted in bone mineral 
density after 12 weeks of age when comparing db/ db mice and genetically matched 
controls. 280 These significant differences as aging ensues may be a result of the initially 
higher levels of osteoclast development in the diabetic model which may, over time, not be 
compensated by high enough levels of bone nodule formation to bring the overall bone 
levels up to 'normal' levels. Although bone nodule formation is higher at the later time 
points, it may not be high enough to compensate for the earlier, lengthier, elevation of 
osteoclast numbers. Thus, there exists a net loss of bone, which becomes noticeable with 
time. These repeated bone turnover cycles may compound and result in a noticeable and 
significant bone mineral density loss over time. This may account for the lesser quality of 
bone found in diabetics, versus that found in healthy individuals. This may also be 
compounded by the loss in quality of bone architecture, which is possibly more easily broken 
down with the addition of any insult to the bone. 
These findings can readily be applied to endodontic lesions in diabetic patients. Bacteria that 
are multiplying in the canal of the affected tooth are producing toxins and other mediators 
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of inflammation which move toward an available exit, be it the apical foramen, lateral or 
accessory canal. The immune reaction that follows is summarized by Grossi and Genco.304 
This egress from the root canal system affects the surrounding bone as well as mounts a 
systemic challenge to immunocompetent cells and cells active in the inflammatory 
cascade.281•282 When these bacterial products interact with mononuclear phagocytic cells it 
results in the activation of a catabolic inflammatory cascade, with synthesis and secretion of 
mediators such as IL-1~, PGE 2, TNF-a, and IL-6. This starts a catabolic cycle of cytokine 
expression and secretion with inflammation, matrix matalloproteinase expression, connective 
tissue destruction, and alveolar bone resorption. These monocytes are 'primed' by AGE-
protein binding. When the monocytes interact they in tum amplify the magnitude of the 
macrophage response to AGE-protein, thereby elevating cytokine production. When 
combined with the finding in this experiment of bone turnover, one would be expected to 
find increased numbers of endodontic lesions in diabetic patients and increased size of these 
lesions. This is in fact what other reasearchers have noted. One study that evaluated the 
presence of carious lesions and periapical lesions in insulin-dependent diabetics found that 
the diabetic group had more periradicular lesions than did those without diabetes. 283 An 
animal study using streptozotocin-induced diabetes in rats demonstrated that root 
resorption, alveolar bone resorption, and inflammation in the apical periodontal ligament 
was more severe in diabetic than control rats.284 Although the streptozotocin model 
represents the type I diabetic model, the similarities between the two models affords us the 
ability to share known information between the two models when it is appropriate, such as 
bone biology. It was also noted that lesions in the diabetic animals were significantly larger 
than those in the controls. These studies illustrate the compromised immune system present 
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in diabetics and would also support the claim that the bone architechure is of poorer quality 
and therefore any bacterial insult would have a more destructive effect. 
Conclusions - Part I - Diabetes Mellitus 
The findings in this study describe bone turnover in the diabetic condtion. Accelerated and 
prolonged bone resorption may occur in diabetic animals followed by an increase in bone 
formation. Based on previous findings by others, the expedited bone remodeling leads to a 
lower density of the bone in diabetics. These findings may partially explain why endodontic 
lesions in diabetics are more prevalent, larger in size and demonstrate delayed healing. 
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Part II: Chemokines 
Introduction 
s lmowledg of the molecular interpla y between various cells of the bod y is continuall y 
advancing further. This is especiall y true of the immune system where cellular response is 
critical in order to develop both acute and chronic inflammatory responses. 285 These 
responses includes cytokines which play a pivo tal role in coordinating the immune system 
and thu have far reaching effects thoughout the bod y. The growing bod y of knowledge in 
this area is illustrating the function of cytokines, specifically chemokines, and how their 
functions overlap. Two mouse models which allow further exploration of this area are the 
genetically displaced monoc yte chemoattractant protein-1 and macrophage inf1ammator 1 
protein-1 a nuce. Experin1ents relating to this section follow that of the diabetic section 
again evaluating osteoclast and osteoblast function and the factors which affect their 
function to have their ultimate effect on the bone. The goal of these experin1ents is to 
deve lop further understanding of their interactions in relation to bone processes, both 
formative and destructive. 
Cytokines 
Cytokines, known historicall y as growth factors, are solubl e intercellular messenger 
molecules released by one cell to act on other cells to carr y out a specific action in their 
target cells.286'287 Cytokines, which are short live d, have three methods of action: (1) 
autocrine, whereby growth factors from one cell type act on identical neighboring cells or 
cells identical in origin, (2) paracrine , whereby growth factors from one cell type act on 
neighboring cells different from itself , and (3) endocrine, whereby growth factors from one 
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cell type act on cells different from itself at a distant location. Binding of the growth factor 
to its target cell receptor initiates an intracellular signal transduction system. In effect, it 
causes a change in the intracellular domain which leads to a transcription factor travelling to 
the nucleus, which then binds to the nuclear DNA and induces the expression of a new gene 
or set of genes. 288'289 These new gene expressions change the cellular characteristics which 
allows them to work in concert with other cells and function as a network, known as a 
cytokine cascade. 
Chemokines 
Chemokines function as secondary pro-inflammatory mediators in response to primary pro-
inflammatory mediators. Chemokines, a large group of peptidic cytokines, act to recmit 
leukocytes to the tissues;290 their attraction of leukocyte family members is highly specific. 
This recruitment causes the host defense mechanisms to be activated and initiates the early 
events of wound healing. Although chemokines were initially considered chemotactic 
cytokines, 291 it is now understood that they serve in migration of inflammatory cells as well 
as angiogenesis, hematopoiesis, and activation of immunocompetent cells.292 
Chemokine Receptors 
Binding of the growth factor and its ligand is termed a ligand-receptor interaction. 
Receptors for chemokines are reviewed by Murphy. 293 Features common to all of them 
include: (1) an extracellular amino-terminus, (2) a polypeptide which loops across the 
membrane seven times, (3) a disulfide bond linking cysteine residues in the first and second 
extracellular loops, and (4) an intracellular carboxyl-terminus. Chemokine receptors are 
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typically located on hemopoietic cells, which include neutrophils, monocytes, lymphocytes, 
myeloid progenitor cell lines, eosinophils and basophils. 290 
The Role of Chemokines in the Immune System 
The immune system contains a number of cells that interact to form a functioning, stable 
system to fight attacks from numerous fronts. Playing an important role are the T-cells 
which develop in the bone marrow and mature in the thymus. They express antibody 
molecules on their surfaces, called T-cell receptors. Included in the T-cells are a number of 
subpopulations that include the helper T, killer T, and memoryT cells. 
The helper T-cell is also known as a helper, helper cell, T helper cell, T-helper lymphocyte, 
CD4 cell, and T 4 cell. The CD4 + T cells function through the release of cytokines in 
response to antigenic stimulation. This allows cellular communication with respect to the 
immune response. This release of cytokines allows the appropriate cell mediated immune 
response to occur. Their primary purpose is regulating the cell-mediated immune response 
to infection. Inherent in their name, helper, they serve other elements of the immune 
system including their primary role of macrophage activation. Antigen presenting cells, 
including B cells, macrophages, and dendritic cells, present the processed antigen to CD4 + T 
cells in the lymphoid tissue which then activates it. Cells in the body which then present 
with that class II 11H:C molecule will be destroyed by the activated macrophages. 
Macrophage activation is an important step to enhanced bacterial killing. This is important 
given that resting, unactivated macrophages do a poor job of phagocytosis compared with 
cytokine activated macrophages. This interaction between the CD4 + cells and macrophages 
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Cytokines Cells of Origin Target Effects on Primary Activity 
Cells Bone 
IL-1 Osteoblast Osteoblast Formation O:>stimulation of APCs 
Macrophage Osteoclast +/- and T cells, 
Fibroblast Resorption inflammation and fever, 
Lymphocyte +/- acute phase response, 
Mast Cell hematopoiesis 
Endothelial Cell 
IL-3 Macrophage Osteoclast Resorption - Growth of 
Lymphocyte hematopoietic 
Mast Cell progenitor cells 
IL-6 Osteoblast Osteoblast Formation - Acute phase response, B 
Macrophage Osteoclast Resorption + cell proliferation, 
Fibroblast thrombopoeisis, 
Lymphocyte synergistic with IL- 1 and 
Mast Cell 1NF on T cells 
Endothelial Cell 
IL-8 Macrophage Osteoblast Resorption + Chemoattractant for 
Fibroblast Osteoclast neutrophils and T cells 
Lymphocyte 
Endothelial Cell 
IL-11 Osteoblast Osteoclast Formation- Synergistic 
Fibroblast Resorption + hematopoietic and 
Mesenchymal Cell thrombopoietic effects 
Lineage 
TNF-a Osteoblast Osteoblast Resorption + Mediates tumour cell 
Macrophage Osteoclast necrosis and destroys 
Fibroblast cancer cells 
Lymphocyte 
Mast Cell 
Endothelial Cell 
TNF-~ Macrophage Osteoblast Resorption + Mediates tumour cell 
Lymphocyte Osteoclast necrosis and destroys 
Mast Cell cancer cells 
M-CSF Osteoblast Osteoclast Resorption + Mediates proliferation, 
Macrophage differentiation, and 
Fibroblast survival of monocyte-
Lymphcyte macrophage lineage 
Mast Cell 
Endothe lial Cell 
bFGF Osteoblast Osteoblast Formation+ Stimulator of PGfa and 
Macrophage FGF-1 and 2 
Fibroblast 
Endothelial Cell 
BMP Osteoblast Osteoblast Formation+ Mediates differentiation 
Fibroblast Osteoclast Resorption - of marrow stromal cells 
RANKL Osteoblast Osteoclast Resorption + Promotes osteoclast 
Fibrob last maturation 
OPG Osteoblast Osteoclast Resorption - Prevents osteoclast 
activation 
Table 3. Effects of cytokines on bone 
+=stinmlation, - =inhibition , +/ - =stimulation or inhibition 
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also forms the basis for the delayed type hypersensitivity response typical with the 
elimination of infections, including Myca bacteria and Gmdida. The activation of the 
monocyte/ macrophage initiates the production of cytokines which then act to recruit 
circulating and resident cells to the area and propagates the spread of inflammation. This 
occurs through proinflammatory mediators and mediators that induce bone 
resorption, 294•295•29 •297 likely accelerated in the presence of multiple factors. 298'299 '300 Matrix-
degrading enzymes, including collagenase, stromelysin, gelatinases, and plasminogen 
activators, are possibly released by cells such as osteoblasts which are activated by 
interleukin- la and TNF-a. A variety of macrophage products can lead to bone resorption 
including IL-la, IL-1~, IL-6 and TNF-a, arachidonic acid metabolites and degradative 
enzymes.301•302•303•304 This then leads to paracrine activation of the osteoclasts, leading to the 
ensuing osteolysis. 
Helper cells can be further subdivided based on the cytokines that they release. This 
includes Thl, Th2 and ThO cells. The Thl cells primarily release IL-2 and gamma interferon 
with antigenic stimulation. The effect of these cytokines is to promote T cell proliferation, 
macrophage activation, delayed type hypersensitivity, and enhance the cytolytic activity of 
NK cells. On the other hand, Th2 cells typically release IL-4, IL-5 and IL-10. Il-4 and IL-5 
tend to shift the response towards IgE or IgA thus directing the response in an allergic 
direction. Tho cells release cytokines with characteristics found in both the Thl and Th2. 
As a result, these are not necessarily three separate groups but overlap to some degree. 
Osteolysis is a result of a number of cellular and humoral factors which influence RANKL 
and OPG expression. Prostaglandins such as PGE 2 have been demonstrated to elevate 
91 
RANK production and reduce OPG release, with the effect of stimulating osteoclast 
formation and bone resorption. Inflammatory cells such as T-cells possibly influence 
osteoclast cliff erentiation and osteolysis by regulating RANKL expression and OPG 
production. It has also been shown that macrophages can produce 1,25 ( OH) 2D3 which has 
been demonstrated to increase the ratio of RANKL to OPG production and thus affect 
osteoclast formation. Some studies have also illustrated the role of cytokines including 
TNF-a, TGF-~, and IL-1, in causing osteoclast formation both in the presence and absence 
ofRANKL. 
Chemokines are made up of two groups based on the position of the cysteine residue, the 
CXC chemokines, or a chemokines, and the CC chemokines, or~ chemokines. The 
members of the CXC chemokines have an amino acid between the cysteines and typically 
are chemotactic for neutrophils. On the other hand, the CC chemokines have adjacent 
cysteines and are found to be chemotactic for monocytes and a small number of 
lymphocytes. 
Monocyte chemoattractant protein 1 (MCP- 1) 
Monocyte chemoattractant protein 1 (Ma- 1) belongs to the CC chemokine family, which 
counts it as its best representative , and exists in two forms, although in vitro both exhibit 
identical activities.305 It attracts target cells which include monocytes, lymphocytes, and 
basophils290 as well as activated T cells, and NK cells.306 As such, this chemokine is a strong 
stimulator of histamine release from basophils and a weak inducer of basophil 
chemotaxis.3on os Despite numerous target cells, the primary target of MCJ)-1 is the 
monocyte. 309 310 
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MCJ>-1 is assumed to play important roles in diseases such as rheumatoid arthritis, bronchial 
asthma, atherosclerosis, pulmonary fibrosis, delayed-type hypersensitivity reactions, sepsis, 
and chronic bacterial infections. 311'312'313J 14'315J 16'317'318'319'320•321 Especially in the area of 
bacterially-induced gingivitis the importance of MCJ>-1 can be demonstrated; its expression 
is high in gingival inflammation. 319.322 Its primary expression in inflamed gingival areas is 
through mononuclear phagocytes and endothelial cells; in healthy gingiva the expression is in 
fibroblasts. MCJ>-1 's importance is outlined by Graves and Jiang 323 with three important 
findings: (1) the majority of mononuclear phagocytes in inflamed tissue express MCJ>-1;322 
(2) MCJ>-1 expression is highly correlated with the degree of gingival inflammation 
present; 319 and (3) MCJ>-1 is the principal monocyte chemoattractant in gingival crevicular 
fluid.324 
In vitro there are a number of monocyte-active chemokines and monocyte-expressed 
receptors as well as ligand-receptor promiscuity that the question has been raised whether 
any one chemokine plays a necessary role in inflammatory disease. However, the activity of 
MCJ>-1 is often required to develop greatest recruitment of monocytes, irrespective of the 
fact that many chemokines have overlapping functions. 325•326'327'328 329'330 New information on 
these intertwined functions is changing. Lu et al. report that the absence of MCJ>-1 causes 
noticeable alterations in cytokine secretion by splenocytes sensitized to Schistosome egg 
antigen (SEA) .331 They postulate that as a result the chemokine redundancy evident with 
receptor binding in vitro may be irrelevant in vivo where specificity is achieved through 
timing and levels of expression. As an example they cite the fact that only MCJ>-1 is 
expressed at high levels in the peritoneum in response to thioglycollate. It would then 
93 
follow that initiatives to affect a single chemokine- receptor pair may be beneficial but would 
depend on isolation of specific chemokine roles. This has been demonstrated with MCP-1 
which they demonstrated can alone affect monocyte movement in several different models. 
Other researchers have shown that genetic deletion of MCP-1 noticeably impairs sustained 
monocyte recruitment in response to a chronic polymicrobial infection. 332 Despite the 
overlapping function they too noted a strong monocyte infiltrate reduction. Interestingly, 
they noted that at early time points the monocyte recruitment was similar in control and 
MCP-1 mice. At later time points however, the MCP-1 chemokine was necessary for 
sustained recruitment. They also noted that circulating leukocytes and macrophages were 
present at numbers considered normal whereas recruitment of polymorphonuclear 
leukocytes (P11Ns) were increased. They also suggested that MCP-1 may be more important 
than other factors for the sustained recruitment than other factors that may play a more 
critical role in the initial aspects of a chronic infection. Despite the genetic deletion of MCP-
1 they noted an increase in bone resorption. As a result of these findings they concluded 
that other cells may contribute to bone resorption. This may include B lymphocytes which 
can cliff erentiate into osteoclasts and T lymphocytes which produce RANKL that stimulates 
osteoclastogenesis and osteoclast activity.333'334 The increased bone resorption Chae et al. 
found is surprising 332 given results by other researchers noting that MCP-1, MCP-2, MCP-3, 
MCP-4, MCP-5, MIP-la, MIP-1~ , 1309, and HCGl all exhibit monocyte chemoattractant 
activity in vitro, but would correlate well with the previous study by Lu et al. and their 
comparison of in vitro and in vivo chemokine interaction. 331 
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Macrophage Inflammatory Protein 
Another CC chemokine family member is macrophage inflammatory protein la and 1~ 
(MIP-la and Jv1IP-l~). Jv1IP-l is a necessary factor for the induction of osteoclast 
differentiation, as evidenced by Scheven et al..335 Their research has shown that specific 
polyclonal antibodies against Jv1IP-la limited the development of 1RAP positive osteoclast 
precursors and multinucleated osteoclasts. Anti-Jv1IP-la antibody treatment resulted in an 
increase in the number of macrophage-like cells, thereby indicating that Jv1IP-la may be 
involved in preosteoclast formation and have an inhibitory effect on progenitor cell 
proliferation. This would thus indicate that chemokines play a vital role in osteoclast 
recruitment and differentiation . Other studies have investigated the effects of chemokines 
on osteoclasts as well.336 They noted inhibition of bone resorption by rat osteoclasts by 
exposure to Jv1IP-la and IL-8 through a reduction in the proportion of osteoclasts resorbing 
bone. Other chemokines, including Jv1IP-2, RANTES, Jv1IP-1~, and MCP-1, did not affect 
resorption. Only Jv1IP-la and IL-8 increased osteoclastic motility and increased the area to 
which osteoclasts spread. This observation would correspond with the effect on resorption 
since motile osteoclast would not be performing a resorptive function. They did not find 
chemokines to affect osteoclast formation or survival. 
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Materials and Methods - Part II 
The chemokine knockout mice, WP and MO\ were bred in the LASC following all federal 
and institutional guidelines. The controls for these experiments, C57BL6, were purchased 
from Jackson Labs, Bar I-Iarbor, ME. Mice were sacrificed by a lethal injection of anesthetic. 
The femur and tibia of the hind limbs were removed under sterile conditions. The 
metaphyseal ends of the bones were removed and the marrow cavities rinsed with 
"complete" media. After filtering, the cells were counted and diluted to the appropriate 
concentration. The procedures were approved by the Institutional Animal Care and Use 
CDmmittee at Boston University. 
Bacteria 
Lipopolysaccharide (LPS) isolated from E scheruhia cdi O 111 :B4 was purchased from List 
Biological Laboratories in a 5.0mg vial. The LPS was diluted utilizing phosphate-buffered 
saline (PBS) to the desired concentrations. 
Marrow Stromal C.ell Cultures - Osteoclasts 
• See 'Marrow Stromal Cell Cultures - Osteoclasts' in Part I - Diabetes Mellitus 
Marrow Stromal C.ell Cultures - Mineralizing Matrix 
• See 'Marrow Stromal Cell Cultures - Mineralizing Matrix' in Part I - Diabetes 
Mellitus 
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Protocols 
Protocol for Bone Marrow C.ell Isolation 
• See 'Protocol for Bone Marrow Cell Isolation' in Part I - Diabetes Mellitus 
• "C,omplete Media" did not include Glutamine or Fungizone 
Protocol for Counting C.ells using Hemacytometer 
• See 'Protocol for C,ounting Cells using Hemacytometer' in Part I - Diabetes 
Mellitus 
Protocol for Osteoclast Formation 
• See 'Protocol for Osteoclast Formation' in Part I - Diabetes Mellitus 
Protocol for Tartrate Resistant Acid Phosphatase (Trap) Staining 
• See 'Protocol for Tartr ate Resistant Acid Phosphatase (Trap) Staining' in Part I -
Diabetes Mellitus 
Protocol for Counting Osteoclasts 
• See 'Protocol for CDunting Osteoclasts' in Part I - Diabetes Mellitus 
Protocol for Mineralizing Matrix (Nodule) Formation 
• See 'Protocol for Mineralizing Matrix (Nodule) Formation' in Part I - Diabetes 
Mellitus 
Protocol for Mineralizing Matrix (Nodule) Staining 
• See 'Protocol for Mineralizing Matrix (Nodule) Staining' in Part I - Diabetes 
Mellitus 
Protocol for Quantifying the Mineralizing Matrix (Nodule) Area 
• See 'Protocol for Quantifying the Mineralizing Matrix (Nodule) Area' in Part I -
Diabetes Mellitus 
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Results - Part II - Chemokines 
1. Dose response of Osteoclast Fo1mation 
The experiments with C57, MCP-knockout mice, and MIP-knockout mice evaluated the 
response of these marrow stromal cells to varying doses of LPS. The combined results of 
these experiments illustrate that there is a relatively static number of osteoclast-like cells 
formed in each of the 3 cultures despite the addition of increasing doses of LPS between a 
concentration of 11 lng/ ml and 3000ng/ ml. Below 9000ng/ ml the statistical calculations 
using Scheff e's post-hoc comparison indicate that there is no statistically significant 
difference between C57, MCP and MIP. Only at 9000ng/ ml is there noted to be a 
statistically significant difference. At this level MCP produces statistically significant more 
osteoclast-like cells than either C57 or MIP, with a=0.05. At this same level, there is no 
statistical difference between C57 and MIP. The osteoclast-like cells for C57, MCP, and 
MIP can be seen in photomicrograph 9a, 96, and 9c, respectively. Lack of stimulation 
produced a lack of osteoclast-like cells as seen in photomicrograph 9d. 
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Legend for Chart 7 
This chart is the result of three separate experiments which used a total of 10 C57 mice, 10 
MCP knockout mice, and 6 MIP knockout mice, all between the ages of 8-12 weeks. 
Stromal cells were isolated from the bone marrow and cultured with "osteoclastogenic 
media." (For complete description see 'Protocol for Osteoclast Formation.') Vitamin D at 
1 OnM and MCSF at 20ng/ ml was included in the culture medium. There were a total of 70 
wells of C57, 71 wells with MCP and 45 wells with MIP knockout marrow cells plated at 5 
million cells per well on 24 well plates. The media was changed every 3 days and the cells 
were stained for TRAP activity and counterstained with hematoxylin after 21 days of culture. 
Under 20x power, a specific area of every well was counted for osteoclasts to determine the 
average number of osteoclasts in the entire well. The standard error was calculated to 
determine the size of the error bars. Statistical analysis using AN OVA was applied to 
determine whether the means of the multiple groups were equal. Since they were not, 
Scheffe's post-hoc comparison was used to determine the pairings that were not equal. In 
this chart, the MCP knockout mice group at 9000ng/ ml was the only group which had 
signficant statistically significant osteoclast numbers, with a=0.05. 
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Photomicrograph 9a. C57 Osteoclast Formation 
Legend for Photomicrograph 9a 
CS 7 mice marrow stromal cell culture stimulated by LPS at 3000ng/ ml seen under 20x 
magnification. The photomicrograph shows multinucleated, TRAP positive osteoclast-like 
cells. This was taken from a representative area. (For complete description see 'Protocol for 
Osteoclast Formation.') 
Photomicrograph 9b. MIP Osteoclast Formation 
Legend for Photomicrograph 9b 
MIP knockout mice marrow stromal cell culture stimulated by LPS at 3000ng/ ml seen under 
20x magnification. The photomicrograph shows multinucleated, TRAP positive osteoclast-
like cells. This was taken from a representative area. (For complete description see 
'Protocol for Osteoclast Formation .') 
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Photomicrograph 9c. MCP Osteoclast Formation 
Legend for Photomicrograph 9c 
MCP knockout mice marrow stromal cell culture stimulated by LPS at 3000ng/ ml seen 
under 20x magnification. The photomicrograph shows multinucleated, TRAP positive 
osteoclast-like cells. This was taken from a representative area. (For complete description 
see 'Protocol for Osteoclast Formation.') 
• 
.,., ... - ,I ~ .,. 
Photomicrograph 9d. Lack of C57 Osteoclast Formation 
Legend for Photomicrograph 9d 
CS7 knockout mice marrow stromal cell culture without stimulation seen under 20x 
magnification. The photomicrograph shows a lack of multinucleated, TRAP positive 
osteoclast-like cells. This was taken from a representative area. (For complete description 
see 'Protocol for Osteoclast Formation.') 
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2. Nodule Formation 
The experiment concerning nodule formation comparisons between C57, MCP and WP 
demonstrated that there are significant differences. The marrow stromal cells of MCP 
knockout mice produced significantly more bone nodule formation than either C57 or WP. 
It is also noted that there is no statistically significant difference between C57 and MIP 
marrow stromal cells. These differences can be seen visually. photomicrograph 10a is C57, 
photomicrograph 106 is MIP and photomicrograph 10c is MCP. 
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Legend for Chart 8 
C57 
This chart is the result of three separate experiments which used a total of 10 C57 mice, 10 
MCP knockout mice, and 6 MIP knockout mice, all between the ages of 8-12 weeks. 
Stromal cells were isolated from the bone marrow and cultured with "complete media;" 
there were a total of 16 wells of C57, 16 wells with MCP and 9 wells with MIP knockout 
marrow cells. (For complete description see 'Protocol for Bone Marrow Cell Isolation.') 
The media was changed on day 4 and then changed to "osteogenic" media on day 7. (For 
complete description see 'Protocol for Mineralizing Matrix (Nodule) Formation.') The 
media was then changed every 2 days and the cells stained for nodule formation on day 21 
by von Kossa's method. Image Pro software was used to count the nodule formation to 
determine average area of growth per well. The standard error was calculated to determine 
the size of the error bars. Statistical analysis using ANO VA was applied to determine 
whether the means of the 3 groups were equal. Since they were not, Scheffe's post-hoc 
comparison was used to determine the pairings that were not equal. In this chart, the MCP 
was the only group which had statistically signficant nodule growth, with a=0.05. These 
differences can be seen pictorall y in photomicrograph 1 0a, CS 7 nodule formation, 
photomicrograph 1 Ob, MIP nodule formation, and photomicrograph 1 0c, MCP nodule 
formation. 
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Photomicrograph 10a. C57 Nodule Formation 
Legend for Photomicrograph 10a 
C57 mice marrow stromal cell culture nodule formation seen under 2x magnification. The 
photomicrograph shows a representative sample. (For complete description see 'Protocol 
for Mineralizing Matix (Nodule) Formation.') 
4 • 
Photomicrograph 10b. MIP Nodule Formation 
Legend for Photomicrograph 10b 
MIP knockout mice marrow stromal cell culture nodule formation seen under 2x 
magnification. The photomicrograph shows a representative sample. (For complete 
description see 'Protocol for Mineralizing Matix (Nodule) Formation.') 
Legend for Photomicrograph 10c 
MCP knockout mice marrow stromal cell culture nodule formation seen under 2x 
magnification. The photomicrograph shows a representative sample. (For complete 
description see 'Protocol for Mineralizing Matix (Nodule) Formation.') 
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Raw Data Processing - Part II - Chemokine Knockout 
Osteoclast Formation 
C57 vs. MIP vs. MCP (November 5, 2002, February 13, 2003 and March 27, 2003) 
Summary: C.Ombined Osteoclast Formation for C57, :MIP, and MQ) (November 5, 2002, 
February 13, 2003, and March 27, 2003) 
Groups Count 
C57 (0 ng/ ml) 96 
C57 (111 ng/ ml) 96 
C57 (333 ng/ ml) 88 
C5 7 ( 1000 ng/ ml) 96 
C57 (3000 ng/ ml) 88 
C57 (9000 ng/ ml) 96 
:MIP (0 ng/ ml) 64 
:MIP ( 111 ng/ ml) 64 
:MIP (333 ng/ ml) 56 
:MIP ( 1000 ng/ ml) 56 
:MIP (3000 ng/ ml) 56 
:MIP (9000 ng/ ml) 63 
MQ) (0 ng/ml) 96 
MQ) (111 ng/ml) 96 
MQ) (333 ng/ml) 96 
MQ) ( 1000 ng/ ml) 96 
Ma (3000 ng/ ml) 99 
MQ) (9000 ng/ ml) 85 
Sum 
52 
563 
629 
477 
479 
1015 
64 
322 
279 
306 
131 
336 
98 
255 
295 
237 
633 
1668 
Average 
0.54 
5.86 
7.14 
4.96 
5.44 
10.57 
1 
5.03 
4.98 
5.46 
2.33 
5.33 
1.02 
2.65 
3.07 
2.46 
6.39 
19.62 
Variance 
2.79 
39.40 
93.20 
20.15 
26.15 
151.65 
4.50 
22.82 
32.49 
70.98 
6.81 
53.45 
19.17 
14.62 
10.65 
16.06 
143.91 
161.88 
ANOV A: C.Ombined Osteoclast Formation for C57, :MIP, and MQ) (November 5, 2002, 
February 13, 2003, and March 27, 2003), cx=0.05 
Source of Variation SS df MS F P-value F crit 
Between Groups 
Within Groups 
Total 
28102.97 
75285.27 
103388.2 
17 
1469 
1653.11 
51.24 
32.25 <0.0001 1.57 
Scheffe's Post-Hoc Comparison: C.Ombined Osteoclast Formation for C57, :MIP, and 
MQ) (November 5, 2002, February 13, 2003, and March 27, 2003) 
Comparisons Observed Critical ·· ·· ·· 1£ 
Mean Difference significant 
Difference 
:MIP 0 vs. :MIP 111 -4.03 6.54 
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WP 0 vs. WP 333 -3.98 6.77 
WP 0 vs. WP 1000 -4.46 6.77 
WP 0 vs. WP 3000 -1.33 6.77 
WP 0 vs. WP 9000 -4.33 6.56 
WP0vs.Mero -0.02 5.97 
WP 0 vs. Mer 111 -1.65 5.97 
WP 0 vs. Mer 333 -2.07 5.97 
WP 0 vs. Mer 1000 -1.46 5.97 
MIP 0 vs. MCP 3000 -5.39 5.93 ........ 
WP 0 vs. Mer 9000 -18.62 6.12 
WP 0vs. C57 0 0.45 5.97 
WP 0 vs. C57 111 -4.86 5.97 
MIP 0 vs. C57 333 -6.14 6.07 ......... 
WP 0 vs. C57 1000 -3.96 5.97 
WP 0 vs. C57 3000 -4.44 6.07 
MIP 0 vs. C57 9000 -9.57 5.97 :: .. :: .. :: .. 
WP111 vs. WP 333 0.04 6.77 
WP 111 vs. WP 1000 -0.43 6.77 
WP 111 vs. WP3000 2.69 6.77 
WP 111 vs. WP 9000 -.30 6.56 
WP 111 vs. Mer 0 4.01 5.97 
WP 111 vs. Mer 111 2.37 5.97 
WP 111 vs. Mer 333 1.95 5.97 
WP 111 vs. Mer 1000 2.56 5.97 
WP 111 vs. Mer 3000 
-1.36 5.93 
MIP 111 vs. MCP 9000 -14.59 6.12 .. , ..... , 
WP 111 vs. C57 0 4.48 5.97 
WP 111 vs. C57 111 
-0.83 5.97 
WP 111 vs. C57 333 -2.11 6.07 
WP 111 vs. C57 1000 0.06 5.97 
WP 111 vs. C57 3000 -0.41 6.07 
WP 111 vs. C57 9000 -5.54 5.97 
WP 333 vs. WP 1000 -0.48 6.99 
WP 333 vs. WP 3000 2.64 6.99 
WP 333 vs. WP 9000 -0.35 6.79 
WP 333 vs. Mer 0 3.96 6.22 
WP 333 vs. Mer 111 2.32 6.22 
WP 333 vs. Mer 333 1.90 6.22 
WP 333 vs. Mer 1000 2.51 6.22 
WP 333 vs. Mer 3000 -1.41 6.18 
MIP 333 vs. MCP 9000 -14.64 6.36 .. .,... :
WP 333 vs. C57 0 4.44 6.22 
WP 333 vs. C57 111 -0.88 6.22 
WP 333 vs. C57 333 -2.16 6.32 
WP 333 vs. C57 1000 0.01 6.22 
WP 333 vs. C57 3000 -0.46 6.32 
WP 333 vs. C57 9000 -5.59 6.22 
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WP 1000 vs. WP 3000 3.12 6.99 
WP 1000 vs. WP 9000 0.13 6.79 
WP 1000 vs. Ma> 0 4.44 6.22 
WP 1000 vs. Ma> 111 2.80 6.22 
WP 1000 vs. Ma> 333 2.39 6.22 
WP 1000 vs. Ma> 1000 2.99 6.22 
WP 1000 vs. Ma> 3000 -0.92 6.18 
MIP 1000 vs. MCP 9000 -14.15 6.36 ......... 
WP 1000 vs. C5 7 0 4.92 6.22 
WP 1000 vs. C57 111 -0.40 6.22 
WP 1000 vs. C57 333 -1.68 6.32 
WP 1000 vs. C5 7 1000 0.49 6.22 
WP 1000 vs. C57 3000 0.02 6.32 
WP 1000 vs. C57 9000 -5.10 6.22 
WP 3000 vs. WP 9000 -2.99 6.79 
WP 3000 vs. Ma> 0 1.31 6.22 
WP 3000 vs. Ma> 111 -0.31 6.22 
WP 3000 vs. Ma> 333 -0.73 6.22 
WP 3000 VS. Ma> 1000 -0.12 6.22 
WP 3000 vs. Ma> 3000 
-4.05 6.18 
MIP 3000 vs. MCP 9000 -17.28 6.36 ::-::•::-
WP 3000 vs. C57 0 1.79 6.22 
WP 3000 VS. C57 111 
-3.52 6.22 
WP 3000 VS. C57 333 
-4.80 6.32 
WP 3000 vs. C57 1000 
-2.62 6.22 
WP 3000 vs. C57 3000 
-3.10 6.32 
MIP 3000 vs. C57 9000 -8.23 6.22 ... .,, .. ,
WP 9000 vs. Ma> 0 4.31 6.00 
WP 9000 vs. Ma> 111 2.67 6.00 
WP 9000 vs. Ma> 333 2.26 6.00 
WP 9000 vs. Ma> 1000 2.86 6.00 
WP 9000 vs. Ma> 3000 
-1.06 5.96 
MIP 9000 vs. M CP 9000 -14.29 6.15 .,:.,, ..,
WP 9000 vs. C57 0 4.79 6.00 
WP 9000 vs. C57 111 
-0.53 6.00 
WP 9000 vs. C57 333 
-1.81 6.10 
WP 9000 vs. C5 7 1000 0.36 6.00 
WP 9000 vs. C57 3000 
-0.10 6.10 
WP 9000 vs. C57 9000 
-5.23 6.00 
Ma> 0 vs. Ma> 111 
-1.63 5.34 
Ma> 0 vs. Ma> 333 
-2.05 5.34 
Ma> 0 vs. Ma> 1000 
-1.44 5.34 
MCP 0 vs. MCP 3000 -5.37 5.30 ::-::•::-
MCP 0 vs. MCP 9000 -18.60 5.51 .... , .,
Ma> 0 vs. C57 0 0.47 5.34 
Ma> 0 vs. C57 111 
-4.84 5.34 
MCP 0 vs. C57 333 -6.12 5.46 ....... , 
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MCJ) 0 vs. C57 1000 -3.94 5.34 
MCJ) 0 vs. C57 3000 -4.42 5.46 
MCP 0 vs. C57 9000 -9.55 5.34 
.. , ...... 
MCJ) 111 vs. MCJ) 333 -0.41 5.34 
MCJ) 111 vs. MCJ) 1000 0.18 5.34 
MCJ) 111 vs. MCJ) 3000 -3.73 5.30 
MCP 111 vs. MCP 9000 -16.96 5.51 
..... , . , 
MCJ) 111 vs. C57 0 2.11 5.34 
MCJ) 111 vs. C57 111 -3.20 5.34 
MCJ) 111 vs. C57 333 -4.49 5.46 
MCJ) 111 vs. C57 1000 -2.31 5.34 
MCJ) 111 vs. C57 3000 -2.78 5.46 
MCP 111 vs. C57 9000 -7.91 5.34 .,, .,, ... 
MCJ) 333 vs. MCJ) 1000 0.60 5.34 
MCJ) 333 vs. MCJ) 3000 -3.32 5.30 
MCP 333 vs. MCP 9000 -16.55 5.51 ., ..... 
MCJ) 333 vs. C57 0 2.53 5.34 
MCJ) 333 vs. C57 111 -2.79 5.34 
MCJ) 333 vs. C57 333 -4.07 5.46 
MCJ) 333 vs. C57 1000 -1.89 5.34 
MCJ) 333 vs. C57 3000 -2.37 5.46 
MCP 333 vs. C57 9000 -7.5 5.34 ,: .. •·· 
MCJ) 1000 vs. MCJ) 3000 -3.92 5.30 
MCP 1000 vs. MCP 9000 -17.15 5.51 .... ,.,. 
MCJ) 1000 vs. C57 0 1.92 5.34 
MCJ) 1000 vs. C57 111 -3.39 5.34 
MCJ) 1000 vs. C57 333 -4.07 5.46 
MCJ) 1000 vs. CS 7 1000 -1.89 5.34 
MCJ) 1000 vs. C57 3000 -2.37 5.46 
MCP 1000 vs. C57 9000 -7.5 5.34 ..... , . ,
MCP 3000 vs. MCP 9000 -13.22 5.47 .. ,.,, ... 
MCP 3000 vs. C57 0 5.85 5.30 .. , .. :.,, 
MCJ) 3000 vs. C57 111 0.52 5.30 
MCJ) 3000 vs. C57 333 -0.75 5.42 
MCJ) 3000 vs. C57 1000 1.42 5.30 
MCJ) 3000 vs. C57 3000 0.95 5.42 
MCJ) 3000 vs. C57 9000 -4.17 5.30 
MCP 9000 vs. C57 0 19.08 5.51 .. ,,,,: 
MCP 9000 vs. C57 111 -5.32 5.51 ., ... .,. 
MCP 9000 vs. C57 333 -6.60 5.62 ::-::-::• 
MCP 9000 vs. C571000 -4.42 5.51 ........ 
MCP 9000 vs. C57 3000 -4.90 5.62 ..... , ... 
MCP 9000 vs. C57 9000 9.05 5.51 ,,,,,: 
C57 0 vs. C57 111 -5.32 5.34 
C57 0 vs. C57 333 -6.60 5.46 "':'''' 
C57 0 vs. C57 1000 -4.42 5.34 
C57 0 vs. C57 3000 -4.90 5.46 
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C57 0 vs. C57 9000 -10.03 5.34 .. ,., .. ,
C57 111 vs. C57 333 -1.28 5.46 
C57 111 vs. C57 1000 0.89 5.34 
C57 111 vs. C57 3000 0.42 5.46 
C57 111 vs. C57 9000 -4.70 5.34 
C57 333 vs. C57 1000 2.17 5.46 
C57 333 vs. C57 3000 1.70 5.57 
C57 333 vs. C57 9000 -3.42 5.46 
C57 1000 vs. C57 3000 -0.47 5.46 
C571000 vs. C57 9000 -5.60 5.34 ., ., .. , 
C57 3000 vs. C57 9000 -5.12 5.46 
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Nodule Formation 
C57 vs. MIP vs. MCP (November 5, 2002, February 13, 2003 and March 27, 2003) 
Summary: Combined Nodule Formation for C57, :MIP, and MO? (November 5, 2002, 
Fe brnary 13, 2003 and March 27, 2003) 
Groups Count Sum Average Variance 
C57 16 
:MIP 9 
MO? 16 
41.64 
33.32 
135.78 
2.60 
3.70 
8.48 
10.48 
10.63 
6.28 
ANOV A: Combined Nodule Formation for C57, :MIP, and MO? (November 5, 2002, 
Februa 13, 2003 and March 27, 2003), a=0.05 
Source of Variation SS df 
Between Groups 
Within Groups 
Total 
300.72 
336.69 
637.41 
2 
38 
MS 
150.36 
8.86 
F P-value F crit 
16.96 <0.0001 3.24 
Scheffe's Post-Hoc Comparison: Combined Nodule Formation for C57, :MIP, and MQ) 
(November 5, 2002, February 13, 2003 and March 27, 2003) 
Comparisons Obseived Critical ::-::-::-if 
Mean Difference significant 
Difference 
MCPvs.MIP 4.78 3.15 :: .. ::-::-
MCPvs. C57 5.88 2.68 .,, ., ... ,
C57 vs. :MIP -1.10 3.15 
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Discussion - Part II - Chemokines 
Previous research on chemokine knockouts has revealed that WP-1 is necessary for 
osteoclast differentiation. This is confirmed in the present experiments in that the level of 
osteoclast development in the WP-1 knockout mice was at stable low levels, irrespective of 
the amount of stimulation by LPS. Even at high levels of LPS, 9000ng/ ml, where the C57 
osteoclast levels increased, the WP knockout cultures maintained constant osteoclast 
numbers, thus demonstrating a statistically significant reduced osteoclast response. WP 
knockout cultures displayed bone formation statistically similar to that of C57 cultures. 
Based on these results we would expect to see less bone loss with high dosage LPS 
stimulation in the WP knockout culture when compared with the C57 culture. 
On the other hand, the in vitro MCI> knockout culture which have normal numbers of 
circulating macrophages, had consistent levels of osteoclast production at various levels of 
LPS stimulation, except at 9000ng/ ml where osteoclast-like cell production was significantly 
increased over the C57 culture. The osteoclast development in the MCI> knockout culture 
matched the C57 culture. Its increased MCI> osteoclast response at higher LPS levels could 
be speculated to be due to a second mechanism of osteoclast development occurring at 
higher levels of stimulation. The significantly increased bone formation noted in the MCI> 
knockout cultures would be consistent with increased bone resorption noted by other 
researchers. Thus, bone resorption triggers bone formation. Given that some mechanism 
has caused increased bone resorption, be it from differentiation derived by other sources, 
another mechanism may occur which would cause increased bone formation. The lack of 
significant numbers of osteoclast numbers in response to the low dose LPS stimulation 
experiment may be due to the fact that the marrow cell populations in these cultures are 
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different from typical inflammatory sites. In inflammatory sites, infiltrating cells such as 
lymphocytes could support inflammatory osteoclast formation by producing a large amount 
of OPGL. Cultures suited to these cells may alter the dose response graphs concerning 
osteoclast formation . 
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Conclusions - Part II - Chemokines 
The findings in this study describe bone turnover in mice lacking either MIP or MCI\ Mice 
that were lacking MIP demonstrated a consistent level of osteoclast formation, despite the 
addition of various concentrations of LPS to the culture. This osteoclast development 
matched that of the controls that MIP knockout mice were paired with . MIP-1 mice also 
produced a similar amount of mineralizing matrix as the control. 
The MCP knockout mice tended to produce increased numbers of osteoclasts , especially at 
higher values of LPS stimulation, when compared with the genetically matched controls. 
Likewise, the nodule formation of the MCP knockout mice was significantly elevated over 
the controls. These findings thus help the understanding of the role of these chemokines 
and their role in bone turnover. 
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